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“For all sorrow or pain is either for something that is truly evil, or for something 
that is apparently evil, but good in reality. Now pain or sorrow for that which is 
truly evil cannot be the greatest evil: for there is something worse, namely, either 
not to reckon as evil that which is really evil, or not to reject it.” 
Summa Theologiae, IaIIae, q.39, a.4.
“To my husband and my sons, 
And to my parents and my brother”
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Abstract
Irina Holma. Long-Term Follow-Up Study Focusing on MDD Patients’ Mainte-
nance Treatment, Adherence, Disability and Smoking. Tutkimus 98. 139 pages. 
Helsinki, Finland 2013. ISBN 978-952-245-836-0 (printed); ISBN 978-952-245-
837-7 (online publication)
This study is a part of a collaborative depression research project between the De-
partment of Mental Health and Substance Abuse Services of the National Institute 
for Health and Welfare, Helsinki (the former Department of Mental Health and Al-
cohol Research of the National Public Health Institute, Helsinki), and the Depart-
ment of Psychiatry of Helsinki University Central Hospital (HUCH), and Peijas 
Hospital in Vantaa. The VDS is a prospective, naturalistic cohort study of 269 sec-
ondary-level care psychiatric out- and inpatients with a new episode of DSM-IV 
major depressive disorder (MDD). 
Overall, the VDS involved screening of 806 adult patients (aged 20-59 years) 
in Peijas Hospital for depressive symptoms beginning February 1, 1997, for a pos-
sible new episode of DSM-IV MDD, and interviewing the 542 consenting patients 
with a semi-structured interview (SCAN, version 2.0 at baseline, at six and 18 
months after baseline and SCID-I at 5 years). Thereby, 269 patients were diagnosed 
with DSM-IV MDD and included in the study, and further interviewed with semi-
structured interviews to assess all additional psychiatric diagnoses. The exclusion 
criteria were DSM-IV bipolar I and II, schizoaffective disorder, schizophrenia or 
another psychosis, organic and substance-induced mood disorders. The 5-year fol-
low-up interviews took place in the psychiatric outpatient units in Vantaa and Hel-
sinki University Central Hospital (HUCH), between April 12, 2002 and April 27, 
2004; 182 patients participated. 
One aim of this 5-year prospective study was to investigate the prevalence, du-
ration and predictors of maintenance pharmacological treatment. A graphic life 
chart was used for the exact duration of the maintenance treatment. To do this, 
an indication for maintenance treatment was defined to exist after a major depres-
sive episode among patients having already had more than three lifetime episodes 
and then achieving full remission for more than 2 months. Treatment was to com-
mence 4 months after achievement of full remission. Only 57% of patients received 
maintenance treatment and only for a small proportion (16%) of the time indicat-
ed. Good adherence to pharmacotherapy in the acute phase independently predict-
ed maintenance treatment.
Next, our aim was to investigate temporal patterns of attitudes and adher-
ence towards pharmacotherapy and psychotherapeutic treatments, and factors 
influencing these patterns among psychiatric MDD patients. During follow-up, 
treatment attitudes and adherence to both forms of treatment were and remained 
mostly positive. While attitudes became more critical over time, adherence to psy-
chosocial treatment improved, but remained unchanged for pharmacotherapy. It 
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was found that employment predicted a positive attitude, and a larger social net-
work good adherence to pharmacotherapy at the last follow-up. Attitudes and ad-
herence to psychosocial treatments were associated with types of personality dis-
orders; cluster B personality disorder symptoms predicted a negative attitude and 
poor adherence, while cluster C symptoms predicted a positive attitude and living 
alone good adherence to psychosocial treatment. 
In addition,  prospective  factors predicting the granting of a long-term dis-
ability pension for psychiatric patients with MDD were investigated. During the 
follow-up of 5 years, one-fifth of the cohort of psychiatric patients with MDD be-
longing to the labour force at baseline was eventually granted a disability pension. 
Higher age, introversion, the perception held at baseline of being unable to work at 
baseline, lack of vocational education and a higher number of comorbid somatic 
disorders all independently predicted the granting of a disability pension. Of those 
receiving such a pension 95.7% had been granted one with major depression as the 
primary diagnosis. 
Lastly, long-term associations between smoking behaviour and depression 
among psychiatric MDD patients  and the co-variation of tobacco smoking and 
MDD with comorbid alcohol use disorder as a potential confounding factor were 
investigated. Smoking in our cohort of MDD patients was very prevalent, only 
one-fourth of subjects had never smoked. Smoking patients differed from non-
smoking patients with regard to age, alcohol use disorders, personality disorders, 
lifetime suicide attempts, personality factors, and social support. The level of de-
pression and smoking did not go hand in hand during the follow-up; they both had 
an independent course. 
Keywords: major depressive disorder, maintenance treatment, treatment atti-
tudes, adherence, disability pension, tobacco smoking, personality disorders, alco-
holism
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Tiivistelmä
Irina Holma. Long-Term Follow-Up Study Focusing on MDD Patients’ Mainte-
nance Treatment, Adherence, Disability and Smoking. [Pitkäaikaistutkimus liitty-
en masennuspotilaiden ylläpitohoitoon, hoitomyöntyvyyteen, työkykyyn ja tupa-
kointiin] Tutkimus 98.  139 sivua. Helsinki, Suomi 2013. ISBN 978-952-245-836-0 
(painettu); ISBN 978-952-245-837-7 (verkkojulkaisu)
Tämä tutkimus on osa Terveyden ja Hyvinvoinnin Laitoksen Mielenterveys- ja 
päihdepalvelut – osaston ja Uudenmaan sairaanhoitopiirin Peijaksen sairaa-
lan psykiatrian tulosyksikön vakavan masennustilan prospektiivista, naturalistis-
ta seurantatutkimusta, Vantaan Depressioprojektia (VDS), jossa on tutkittu 269 
DSM-IV luokituksen mukaista vakavaa masennustilaa sairastavaa psykiatrista avo-
hoito- ja sairaalapotilasta. 
Tutkimuksen alussa seulottiin 1.2.1997 lähtien 806 aikuista potilasta (ikä 20–
59 vuotta) masennusoireiden suhteen; alun perin tutkimukseen suostuivat 542 
potilasta. Tutkimukseen valikoitui seulontavaiheen jälkeen 269 potilasta, jotka 
täyttivät ajankohtaisen vakavan masennustilan oirekriteerit; heitä tutkittiin puo-
listrukturoiduin haastattelumenetelmin sisäänottovaiheessa ja 6- ja 18-kk seuran-
noissa SCAN-haastattelulla sekä viiden vuoden seurannassa SCID-I- haastattelul-
la. Poissulkutekijöitä olivat DSM-IV kaksisuuntainen mielialahäiriö tyyppi I ja II, 
skitsoaffektiivinen häiriö, skitsofrenia tai muu psykoosi, sekä orgaaninen tai kemi-
allisen aineen aiheuttama mielialahäiriö. Viisivuotisseurantahaastattelut suoritet-
tiin 12.4.2002–27.4.2004 Vantaan psykiatrisilla poliklinikoilla ja HYKS psykiatrian 
poliklinikalla; 182 potilasta osallistui haastatteluihin. 
Tämän tutkimuksen yhtenä tavoitteena oli tutkia masennuslääkityksen yllä-
pitohoidon toteutumista, kestoa ja ennustetekijöitä. Tutkimuksessa käytettiin. mm 
graafista elämänjana-menetelmää, jonka avulla ylläpitohoidon toteutumista pys-
tyttiin tutkimaan ajan suhteen. Indikaationa ylläpitohoidolle pidettiin hoitosuosi-
tusten mukaisesti kolmea elinaikaista vakavan masennustilan jaksoa ja uutta ma-
sennusjaksoa vähintään kaksi kuukautta kestäneen oireettoman vaiheen jälkeen. 
Täydellä remissiolla tarkoitettiin masennuksen suhteen täysin oireetonta tilaa. 
Osittaisessa remissiossa sai olla 1-4 yhdeksästä oireesta. Masennustilassa oli viides-
tä yhdeksään oiretta. Ylläpitohoito laskettiin alkaneeksi jatkohoitovaiheen jälkeen, 
kun toipuminen oli jatkunut vähintään neljä kuukautta. Totesimme, että seuran-
nan aikana vain 57 % potilaista, joille ylläpitohoito olisi ollut indisoitu, saivat sitä 
ja vain hyvin lyhyen (16 %) ajan indisoidusta ajasta. Hyvä lääkehoitomyöntyvyys 
hoidon akuutissa vaiheessa ennusti toteutunutta ylläpitohoitoa.
Seurannan aikana tutkittiin myös hoitoasenteita ja -myöntyvyyttä. Suurim-
malla osalla potilaista oli positiivinen asenne sekä lääkehoitoa, että psykoterapeut-
tista hoitoa kohtaan, mutta asenteet tulivat ajan kuluessa jonkun verran kriitti-
semmiksi. Hoitomyöntyvyys psykososiaaliseen hoitoon tuli paremmaksi, kun taas 
lääkehoitomyöntyvyys pysyi samanlaisena. Työssäolo ennusti positiivista asennetta 
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ja laaja sosiaalinen verkosto hyvää lääkehoitomyöntyvyyttä. Asenne ja myöntyvyys 
psykososiaalisen hoidon suhteen liittyivät persoonallisuudenhäiriöihin: ryhmä B 
persoonallisuushäiriö ennusti negatiivista asennetta ja huonoa hoitomyöntyvyyt-
tä, kun taas ryhmän C ennusti positiivista asennetta. Yksin asuminen taas ennusti 
hyvää hoitomyöntyvyyttä psykososiaalisen hoidon suhteen.
Seurannan aikana tutkittiin myös masennuspotilaiden riskitekijöitä työkyvyt-
tömyyseläkkeelle jäämisen suhteen.  Viiden vuoden seurannassa viidesosa potilaista, 
jotka kuuluivat työvoimaan ennen tutkimuksen alkua, jäi työkyvyttömyyseläkkeel-
le. Korkeampi ikä, introversio, oma käsitys työkyvyttömyydestä, ammattikoulutuk-
sen puute ja somaattinen oheissairaus ennustivat eläkkeelle jäämistä. Lähes kaikilla 
(95,7 %) oli vakava masennustila ensisijaisena syynä työkyvyttömyyseläkkeeseen.
Lisäksi tutkittiin vakavan masennustilan ja tupakoinnin pitkäaikaisyhteyksiä, 
alkoholihäiriötä mahdollisena sekoittavana tekijänä ja niiden keskinäisiä suhteita 
ajan kuluessa. Tupakointi oli tutkimuskohortissamme hyvin yleistä: vain neljäsosa 
potilaista ei ollut koskaan polttanut. Tupakoivat potilaat erottuivat tupakoimatto-
mista merkitsevästi iän, alkoholihäiriön, persoonallisuudenhäiriön, itsemurhayri-
tysten, temperamentin ja koetun sosiaalisen tuen osalta. Masennustilalla ja tupa-
koinnilla oli kummallakin itsenäinen kulku, jonka vaikutukset toisiinsa välittyivät 
alkoholinkulutuksen kautta.         
Avainsanat: vakava masennustila, ylläpitohoito, hoitoasenteet, hoitomyöntei-
syys, työkyvyttömyys, tupakointi, persoonallisuushäiriöt, alkoholihäiriö.
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1 Introduction 
There are seven basic emotions: anger, disgust, fear, joy, surprise, contempt and 
sadness (Ekman, 1972; Tomkins, 1984). Normally, a lowered mood usually does 
not markedly affect one´s functional, social, or occupational ability or social ad-
justment. More severe depressive symptoms and disorders can be seen as a contin-
uum of those normal negative feelings.  
Major depressive disorder (MDD) is considered as a severe highly prevalent, 
aetiologically multifactorial, clinically heterogeneous illness whose picture is char-
acterized by a sad mood and an inability to experience pleasure, often including 
serious abnormalities in cognition and physiological function. It imposes a sub-
stantial burden by inflicting recurrent pain and suffering on individuals and their 
families.  MDD is a commonly occurring and burdensome disorder and one of 
the most important mental disorders in terms of public health impact. About a 
fifth of the population (Kessler et al., 1994; Kessler et al., 2003), women more often 
than men, will experience a clinically significant episode of MDD at some point in 
their lives. MDD involves a marked risk of functional disability (Lopez et al., 2006; 
Rytsälä et al., 2006) and adversely affects interpersonal relationships (Wade and 
Cairney, 2000). The Global Burden of Disease Study estimated in 1990`s that MDD 
is worldwide the fourth leading cause of functional impairment, and days lost from 
work (Murray and Lopez, 1997).  In 2004 MDD was considered to be the third 
leading illness in terms of global disease burden, and by the year 2030 it is predicted 
to be the leading cause of functional disability and the major disease or injury bur-
den followed by ischaemic heart disease and road traffic accidents (WHO, 2004).  
Effective MDD treatments have been available for decades. During the last 
50 years, effective medicines, different types of psychotherapy and electroconvul-
sive therapy have been found and developed to treat depression. But only a realized 
treatment is useful for patients. Poor adherence to treatment for depression is com-
mon, and an important limiting factor to what can be achieved by treatment. Un-
derstanding factors influencing attitudes and adherence is important to better en-
gage patients in treatment and improve their prognosis. 
MDD is usually recurrent. National practice guidelines recommend mainte-
nance pharmacotherapy for most patients with a history of three or more ma-
jor depressive episodes or who are vulnerable to future recurrences (Depression 
Guideline Panel, 1993; Geddes et al., 2003; Isometsä et al., 2003; APA, 2010). Main-
tenance therapy is an effective tertiary preventive intervention. Occasionally there 
is debate on whether antidepressant medications are needed. However, the ma-
jority of studies on pharmacotherapy are from acute stage studies (Geddes et al., 
2003), and there is a lack of  long-term maintenance treatment studies with con-
temporary madications (Viguera et al., 1998). This fact is likely to cause confusion. 
18
Long-Term Follow-Up Study Focusing on MDD Patients’ 
Maintenance Treatment, Adherence, Disability and Smoking
THL – Reserach 98 • 2013
The high disease burden is also understandable from considerations of the na-
ture and course of depression. Previously viewed as an acute and self-limiting ill-
ness, it is now clear that depression is not only highly prevalent but also a chron-
ic, recurrent and comorbid illness. One comorbid illness is nicotine dependence. 
The relationship between smoking and depression is complex, smoking appears to 
increase the risk of depression approximately twofold (Lindeman et al., 2000; Bre-
slau et al., 2004). However, long-term successful cessation of smoking might pro-
vide protection from depression (Rose, 2009; Berlin et al., 2011; Korhonen et al., 
2011; cMDermott et al., 2013).
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2.1 Definition of depression
2.1.1 Depression as an affect or symptom
Sadness is  one of the seven basic emotions (Ekman, 1972; Tomkins, 1984) of hu-
man being that can affect a person’s thoughts, behavior, feelings and physical well-
being.  A person with depression displays a cognitive bias towards negative infor-
mation and away from positive information, thus contributing to the maintenance 
of a depressed mood state (Disner et al., 2011). A depressed person may lose in-
terest in activities that once were pleasurable, experience loss of appetite or over-
eating, or problems concentrating, remembering details or making decisions; and 
may contemplate or attempt suicide, have insomnia, excessive sleeping, fatigue, loss 
of energy, or aches, pains or digestive problems that are resistant to treatment (Na-
tional Institute of Mental Health, 2009). In addition, three main points of view 
from evolutionary psychiatry exist: 1) a depressive reaction develops as a part of in-
fectious defence (advantage: a protection against infections harms social and psy-
chological functions) (Anders et al., 2012; Raison and Miller, 2013) 2) depression is 
a mechanism that helps to separate from impossible objectives (Nesse, 2000), and 
3) depression protects a membership in a social group (Allen and Badcock, 2006).
A depressed mood state does not necessarily implicate a psychiatric disorder. 
It is a normal reaction to disappointment, loss or other painful life events. It may 
be a symptom of some medical conditions, for example, pancreatic carcinoma and 
a side-effect of some medical treatments, for example interferon treatment for C-
Hepatitis. A depressed mood is also a main or common feature of certain psy-
chiatric syndromes such as major depressive disorder.  There has been debate on 
whether depression and grief are the same thing. Grief is considered as a transient 
experience, which however can be prolonged and be pathological especially among 
those with a history of psychological symptoms, even before the grief-provoking 
event has occurred (Bonanno et al., 2002; Bonanno and Mancini, 2008). 
2.1.2 Diagnosis of major depressive disorder (MDD)
There are currently two diagnostic classification systems in use, the DSM-IV 
(American Psychiatric Association 2010), which has been used in this thesis and 
ICD-10 (World Health Organization 2007; Tautiluokitus 2010). DSM-IV MDD is 
characterized by having one or more major depressive episodes lasting at least two 
weeks. In order to warrant a diagnosis of MDD, persistent depressive mood or sig-
nificant loss of interest or pleasure are the required core symptoms, which must 
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be accompanied by at least four associated symptoms (total of 5 or more symp-
toms) during most of the day or nearly every day, e.g. significant weight or appe-
tite change,  insomnia or hypersomnia,  psychomotor agitation or retardation, fa-
tigue or loss of energy, feelings of worthlessness or extreme or inappropriate guilt, 
a diminished ability to think or to concentrate or indecisiveness, and  recurrent 
thoughts of death or suicidal ideation, or a suicide attempt or a specific plan for 
committing suicide (APA, 2003). Moreover, the symptoms must cause clinically 
significant distress or impairment in social, occupational, or other important are-
as of functioning and should not be due to the direct physiological effects of a sub-
stance or a general medical condition. In addition, mood-incongruent delusions 
or hallucinations, bipolar mixed episode, or bereavement must be ruled out. The 
diagnosis of MDD in both DSM-IV and ICD-10 (WHO, 2007) are almost com-
patible. However, compared with DSM-IV, ICD-10 splits one criterion (feelings of 
worthlessness and unreasonable guilt), requires one symptom less for diagnosis, 
and also includes fatigue or loss of energy among the core symptoms. In this thesis, 
unless otherwise specified, depression refers to unipolar DSM-IV MDD.
2.1.3 Subgroups of MDD and diagnosis of other depressive 
disorders
There are three levels of severity of MDD in DSM-IV: mild, moderate or severe 
(with or without psychotic features) based on the number and severity of the diag-
nostic criteria, and gradation of functional disability and distress. Psychotic MDE 
includes delusions or hallucinations, where the psychotic features are mood con-
gruent or mood incongruent (APA, 2000).  The melancholic features specifier  in-
cludes  loss of pleasure in all, or almost all, activities,  lack of reactivity to usually 
pleasurable stimuli,  a distinct quality of the depressive mood,  depression regular-
ly worse in the morning, early morning awakening, marked psychomotor change, 
either retardation or agitation, significant loss of appetite or weight loss, and ex-
cessive or inappropriate guilt (APA, 2000). Melancholic features and psychotic fea-
tures may represent a distinctive form of severe depression arising from a differ-
ent pathophysiology than other forms of depression (Parker et al., 2000; Parker and 
Manicavasagar, 2005). The validity criteria of the atypical features include mood 
reactivity plus at least two of the following four symptoms: significant weight gain 
or increased appetite, hypersomnia, severe lethargy, and a pathological rejection 
sensitivity (APA, 2000). Seasonal pattern depression has an apparent regular onset 
and disappearance during certain times of the year. In the Northern hemisphere 
the most common pattern is autumn or winter depression (SAD or seasonal af-
fective disorder). Postpartum depression may develop into an MDE if the onset 
is within 4 weeks after delivery (APA, 2000). Dysthymic disorder in DSM-IV con-
sists of chronic but milder symptoms than in MDE. Dysthymia features  crite-
ria include  a depressed mood for most of the day or for more days than not for 
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at least two years;  the presence, while depressed, of at least two of the following: 
poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low 
self-esteem,  poor concentration or difficulty in making decisions, or feelings of 
hopelessness (APA, 2000). When an intense episode of depression occurs on top 
of dysthymia the state is called “double depression” (Klein et al., 2006). A num-
ber of subjects with disabling depressive symptoms fail to meet the diagnostic cri-
teria for MDE or dysthymia, some of these subsyndromal conditions are included 
in the category depression not otherwise specified (NOS), which includes several 
forms of briefer or milder periods of depression (APA, 2000). Appendix B in DSM-
IV (APA, 2000) defines diagnostic criteria for recurrent brief depressive disorder, 
where the episodes are identical to MDE in the number and severity of symptoms 
but do not meet the 2-week duration requirement lasting at least 2 days but less 
than two weeks. Episodes must recur at a minimum of once a month for a period 
of 12 consecutive months. Depression can also include a few depressive symptoms 
diagnosed as minor depressive disorder (MinD), although not considered an offi-
cial clinical diagnosis, the American Psychiatric Association defined research diag-
nostic criteria in Appendix B of DSM-IV (APA, 2000). Those patients have never 
met the criteria of MDE or manic episode.
2.2 Epidemiology of MDD                                                                                               
2.2.1 Prevalence of MDD 
Major depressive disorder is a common disorder. Numerous epidemiological stud-
ies have estimated the prevalence of depressive disorder. Retrospective lifetime 
prevalence of MDD in any general population studies varies from 12% to 17% 
(Kessler et al., 1994; Bijl et al., 1998; Kessler et al., 2003; Alonso et al., 2004; Ha-
sin et al., 2005). In prospective epidemiological studies, the lifetime prevalence of 
MDD has been two-fold compared to retrospective studies (Moffitt et al., 2009) 
The 12-month prevalence of MDD has been 4 to 9% (Offord et al., 1996; Salokan-
gas et al., 1996; Bijl et al., 1998; Lindeman et al., 2000; Kessler et al., 2003; Alonso et 
al., 2004; Pirkola et al., 2005). National Comorbidity Survey Replication (NCS-R), 
performed in 2001-2002, found a 12-month prevalence of 6.6% and lifetime prev-
alence of MDD of 16.2% among U.S. adults (Kessler et al., 2003). In Europe, The 
European Study of the Epidemiology of Mental Disorders/ Mental Health Disabil-
ity (ESEMeD/MHDEA 2000) reported from six countries a 12-month prevalence 
of 4% and lifetime prevalence of 13% (Alonso et al., 2004). In Finland, the Health 
2000 project reported a 12-month prevalence of 4.9% and lifetime prevalence of 
17.7% (Pirkola et al., 2005a; Suvisaari et al., 2009), while the 12-month prevalence 
was 9.3% in the Finnish Health Care Survey (FINHCS) (Lindeman et al., 2000). 
In one domestic study, the Tampere Depression (TADEP) Study the 1-year preva-
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lence rate of clinical depression was 20% patients of primary care patients where-
as lifetime clinical depression was found in a tenth of primary care patients, and in 
one-half of patients in community mental health centres (Salokangas et al., 1996). 
The difference in prevalences may be due to the methodological factors, such as di-
agnostic criteria, different instruments and sampling methods. The prevalence of 
MDD for females is about twice as high as for males (Paykel et al., 2005); it is fair-
ly low until the early teens, when it begins to rise in roughly linear fashion (Kes-
sler et al., 1994), the median age of onset being approximately 30 years (Kessler et 
al., 2003).
2.2.2 Epidemiology of treatment of MDD
Despite of the high prevalence of MDD, a large proportion of depressed patients 
are still not receiving treatment. The ESEMed project (Alonso et al., 2004) found 
that only 36.5% of patients with mood disorders had consulted formal health ser-
vices. The Mini-Finland Survey reported that only one third of those diagnosed 
with depression were actually receiving treatment although they were assessed to be 
in need of it (Lehtinen et al., 1990; Lehtinen and Joukamaa, 1994). Half of the treat-
ment received was assessed as inadequate. Of the depressive subjects, only one-third 
received some kind of treatment. Two of five suffering even from the most severe 
MDE did not use formal the health services for depression. More recently, the more 
severe, long-lasting, and disabilitating the depression, the more probable was the use 
of health services for major depression, (Hämäläinen et al., 2004) The NESARC re-
search found that approximately 60% of patients with MDD reported treatment spe-
cifically for the disorder; women were more likely to be treated than men. The Finn-
ish Health Care Survey, consisting of a random population sample of MDD sufferers 
reported only 24% use of antidepressants, and 17% received psychosocial treatment. 
According to the Health 2000 project of subjects with MDD only 34% used health 
services (Hämälainen et al., 2008; Hämäläinen et al., 2009).In VDS, among patients 
in psychiatric care, most patients (88%) received antidepressants in the early acute 
phase, but about half (49%) terminated treatment prematurely. 
A recent Finnish study reported improved detection and pharmacotherapy 
of major depression from 1989 to 2001 in psychiatric outpatient care, and con-
cluded problems in care to be more related to suboptimal intensity and monitor-
ing of treatment than to mere lack of treatment (Sorvaniemi et al., 2003).   Among 
US adults in the NCS-R, health care treatment for depression was found to be ad-
equate in only a fifth of the cases with 12-month MDD (Kessler et al., 2003). In a 
World Mental Health Survey, although disorder severity was correlated with prob-
ability of treatment in almost all countries, 35.5% to 50.3% of serious cases in 
developed countries and 76.3% to 85.4% in less-developed countries received no 
treatment in the 12 months before the interview (Demyttenaere et al., 2004).
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2.3 Aetiology and pathogenesis of MDD 
2.3.1 Multifactorial model
MDD is considered to be a clinically heterogeneous, multifactorial disorder influ-
enced by risk factors from multiple domains that are interrelated through devel-
opmental pathways (Kendler et al., 2002; Kendler et al., 2006; Belmaker and Agam, 
2008). In the aetiology of depression life stress seems an important component, but 
also requires other vulnerability factors to explain the onset (Monroe et al., 2001). 
The associations among the psychopathological and biological endophenotypes 
are discussed with respect to specificity, temporal stability, heritability, familiarity, 
and clinical and biological plausibility.  Neurochemical signal transduction mech-
anisms, neural circuits, psychosocial stressors and their complex interaction pose 
a major impediment to elucidating the genetic and neurobiological basis of this 
common, severe, and often life-threatening illness (Hasler et al., 2004). 
2.3.2 Heritability and genetic risk factors  
A combination of genetic and environmental risk factors probably contributes to 
MDD. The heritability or the proportion of variation due to genetic factors for 
MDD has been reported to be in the 20–45% range (Sullivan et al., 2000) or 41–
50% (Kendler et al., 2011) and  has been on average somewhat higher in women 
(40–45%) compared to men (25-30%). (Sullivan et al., 2000; Kendler et al., 2006c), 
but even 70% has been reported in twin studies (McGuffin et al., 2007). The her-
itability can be even up to 75% in clinical cohorts of subjects with more recurrent, 
difficult depressive episodes, and early age at onset (Uher, 2008). A proposed model 
of depression incorporates the interacting genetic and environmental factors over 
the course of life and provides an explanatory framework for the heterogeneous ae-
tiology of depression. Early environmental influences act on the genome to shape 
the adaptability to environmental changes in later life (Caspi et al., 2003; Uher and 
McGuffin, 2008; Caspi et al., 2010). Recent genetic studies have contributed by the 
discovery of multiple genes that predict increased risk for depression. Special inter-
est has been focused on the candidate genes, transporter gene (5-HTTLPR), which 
associate with the probability of patients  responding to antidepressant treatment 
(Caspi et al., 2003; Caspi et al., 2010), glucocorticoid receptor gene (Frodl et al., 
2012; Massart et al., 2012), brain-derived neurotrophic factor gene (Kaufman et 
al., 2006; Chen et al., 2012) and their possible interactions (Kim et al., 2007). The 
potential mechanisms include a heightened reactivity to stress stimuli mediated by 
the serotonergic nerve system (Canli and Lesch, 2007), and the regulation of hy-
pothalamus-pituitary-adrenal (HPA) axis (Gotlib et al., 2008; Chen et al., 2009; El 
Hage et al., 2009). 
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According to one hypothesis, the polymorphism of the promoter region of the 
5-HTR2A gene is associated with MDD patients (Choi et al., 2004). Gene-environ-
ment interactions have been reported, e.g. the serotonin receptor 2A gene may be 
involved in the development of depression by influencing the ability of individu-
als to use environmental support (Jokela et al., 2007). Functional polymorphism 
in the brain derived neurotrophic factor gene (BDNF Val66Met) modulates the in-
fluence of stressful life events on adolescent depressive symptoms (Elovainio et al., 
2007; Chen et al., 2012). In the last decade the serotonin transporter gene promoter 
polymorphism (5-HTTLPR) was likely the most studied genetic variant most stud-
ied as a predictor of antidepressant response. Drug response may depend of genet-
ic differences (Porcelli et al., 2011). 
2.3.3 Early and recent psychosocial risk factors
Psychosocial risk factors for MDD can be divided into early and recent risk factors. 
The risk for adults may be increased by a wide range of negative life events in child-
hood ranging from physical or sexual abuse and other adult psychopathology, pa-
rental death and any history of having experienced poor parenting, parental loss or 
separation, and depression of parents (Lieb et al., 2002; Gladstone et al., 2004; Vei-
jola et al., 2004; Kendler and Prescott, 2006). 
The impact of adverse environmental factors during childhood seems to be 
composed of a wide range of factors from direct causal associations to complex in-
teracting environmental effects (Pirkola et al., 2005). Childhood adversities might 
be worse if combined with adult adverse life-events (Korkeila et al., 2005). Poor 
parenting may increase the risk of MDD through individual specific environment, 
i.e. individuals respond to parenting in different ways directed in part by genetical-
ly predisposed characteristics e.g. temperament (Kendler and Prescott, 2006). Most 
MDD risk factors had a greater impact on women than on men on the risk of MDD 
and were not restricted to a specific class of risk factors (Stegenga et al., 2012).
Childhood adversities have been found to associate with adult depression-
prone personality characteristics (Korkeila et al., 2004), and with an increased like-
lihood of experiencing a high number of life events in adulthood and their per-
ceived as burdensome (Korkeila et al., 2010). Interaction between life-events and 
neuroticism has been found, and that neuroticism strongly reflects a patint’s sus-
ceptibility to MDD (Kendler et al., 2006). The childhood adversity-depressive-
ness associations are partly mediated by adult risk factors supporting a pathway 
from childhood adversities to depressiveness through adult risk factors (Korkeila 
et al., 2005). Of four psychological dimensions of life-events (entrapment, danger, 
loss and humiliation), high ratings of loss and humiliation have been related with 
increased risk for depression among individuals with high-threat events and the 
combination of high ratings of events and loss creates the highest risk for depres-
sion (Farmer and McGuffin, 2003; Kendler and Prescott, 2006). Current stress to-
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gether with genetic vulnerability and temperamental factors may be one of the key 
reasons for propensity for MDD (Kendler et al., 2002; Kendler et al., 2006a). Men 
have been more affected by divorce and work difficulties, and women more sensi-
tive to events in their proximal social network events (Kendler and Prescott, 2006). 
Different types of difficulties may lead to different profiles of depressive symptoms 
(Keller et al., 2007). Low social support has also been found to increase risk for de-
veloping future episodes of MDD (Kendler et al., 2006a). Depression may in turn 
have significant negative consequences on the social support available (Coryell et 
al., 1993; Leskelä et al., 2008). According to recent findings, the ability to receive 
and respond to support may be influenced by early negative experiences and rela-
tionships with significant others. In the VDS, 91% of the patient’s connected the 
onset of MDE with some adverse event, although no clustering of live events ap-
peared to associate with the time of onset (Leskelä et al., 2004).
2.3.4 Personality and temperamental factors
Temperament is the combination of the mental, physical, and emotional traits of 
a person; it has been seen as a core that develops early and that forms the founda-
tion for an individual’s later personality. There are several personality trait theo-
ries, each with a different emphasis and number of temperament dimensions. In 
the Big Five- theory personality is conceived as (a) an individual’s unique variation 
in the general evolutionary design for human nature, expressed as a developing 
pattern of (b) dispositional traits, (c) characteristic adaptations, and (d) self-de-
fining life narratives, complexly and differentially situated (e) in culture and social 
context. The five principles suggest a framework for integrating the model of per-
sonality traits with those self-defining features of psychological individuality con-
structed in response to situated social tasks and the human need to make meaning 
in culture (McAdams and Pals, 2006). Two widely studied personality dimensions 
describing negative and positive trait entities, neuroticism, and extroversion have 
been included in the Five Factor Model together with agreeableness, conscientious-
ness and openness to new experience (Goldberg, 1993).
Cloninger has described four dimensions of temperament, i.e. novelty seek-
ing, harm avoidance, reward dependence, persistence, and dimensions of character 
associated with different aspects of self-concept, i.e.  self-directedness, cooperative-
ness, and self-transcendence (Cloninger et al., 1993). Personality as the visible as-
pect of one’s character as it impresses others can be conceptualized as a large entity 
of individual differences including values, motives, attitudes, needs, coping mech-
anisms, capabilities, attainments and self-esteem. Personality develops from tem-
perament through experiences, maturation and interaction with the environment 
(Pervin et al., 2005). Personality dimensions have been found to influence the pro-
pensity for depression. High neuroticism has been regarded as a risk factor for de-
pression (Angst and Clayton, 1986; Hirschfeld et al., 1989; Boyce et al., 1991; Shea 
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et al., 1996; Fanous et al., 2007). Neuroticism may limit the psychosocial and psy-
chiatric care received (Hopwood et al., 2008). Moreover, extraversion has been re-
ported to have a negative correlation with depressive disorders  (Hirschfeld et al., 
1989; Cox et al., 2004; Kendler et al., 2006) and to even exert some protective effects 
against depression (Farmer et al., 2002). 
However, the role of extroversion as a risk factor for depression is more ob-
scure than that of neuroticism, as prospective studies (Angst and Clayton, 1986; 
Hirschfeld et al., 1989; Boyce et al., 1991; Kendler et al., 1993b; Fanous et al., 2007) 
have not proved low extroversion to be a risk factor. The relationship between per-
sonality and affective disorders is complex. Personality features may have a com-
mon cause with affective disorders, may predispose an individual to affective dis-
orders, be shaped by repeated episodes of the illness, modify the clinical picture of 
the illness, be an attenuated expression of the disorder or be state-dependent con-
comitants of affective disorders (Shea and Yen, 2003; Brandes and Bienvenu, 2006). 
2.3.5 Imaging findings in patients with MDD.
Many brain regions have been implicated in regulating emotions and thus also 
postulated to mediate the symptoms of depression (Nestler et al., 2002). A me-
ta-analysis which analysed studies that used magnetic resonance imaging or x-ray 
computed tomography showed that MDD was associated with lateral ventricle en-
largement; larger cerebrospinal fluid volume; smaller volumes of the basal ganglia, 
thalamus, hippocampus, frontal lobe, orbitofrontal cortex, and gyrus rectus. Pa-
tients during depressive episodes had significantly smaller hippocampal volume 
than patients during remission (Martinot and Mana, 2011). In another meta-anal-
ysis MDD was associated with reduced rates of deep white matter hyperintensities, 
increased corpus callosum cross-sectional area, and smaller hippocampus and ba-
sal ganglia (Kempton et al., 2011).  Recently a meta-analysis showed a relative hy-
poactivation of the sensorimotor cortices in MDD (Delvecchio et al., 2012). One 
meta-analysis identified 4 consistent locations of decreased fractional anisotropy in 
patients with MDD: white matter in the right frontal lobe, right fusiform gyrus, left 
frontal lobe and right occipital lobe. Fibre tracking showed that the main fascicles 
involved were the right inferior longitudinal fasciculus, right inferior fronto-occip-
ital fasciculus, right posterior thalamic radiation and interhemispheric fibres run-
ning through the genu and body of the corpus callosum (Liao et al., 2012) or in-
volving the superior frontal gyrus, insula and putamen (Tao et al., 2013). MRI and 
fMRI studies have also revealed decreased white matter volumes in the left anteri-
or cingulated gyrus and right middle frontal gyrus among elderly MDD patients 
(Tham et al., 2010), and also in middle-aged MDD patients an enlarged middle 
genu area of corpus callosum has been revealed (Kieseppä et al., 2010). Late-life de-
pression (LLD) has tended to be associated with smaller volumes in circumscribed 
frontal and subcortical structures with the most robust differences being found 
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in thalamic volume (Bora et al., 2012). More recently, white matter abnormalities 
have been revealed also in first-episode, treatment-naïve young adults in the fron-
tal, temporal and parietal lobes with a modern MRI technique, diffusion tensor 
imaging (DTI) (Ma et al., 2007). Postmortem studies have also revealed a decrease 
in gliacells (astrocytes and oligodendrocytes) especially in the amygdala and pre-
frontal regions of the brain (Rajkowska and Miguel-Hidalgo, 2007; Townsend et 
al., 2010). It seems these changes can sometimes be found already in the early stage 
of illness, and in young adolescents with a familial risk of depression. 
2.3.6 Neurochemical, neurotrophic, and neuroendocrinological 
findings 
Even though depression is associated with a number of biological changes, none 
of them is now a positive biomarker for depression as MDD is a biologically heter-
ogeneous disorder (Goltser-Dubner et al., 2010; Schneider et al., 2011). The best-
known changes are related to the HPA-axis function and immune system activa-
tion. Howevwr, according to one Finnish research, depressive symptoms may be 
partly responsible for inflammatory processes, and inflammatory processes may 
induce depressive symptoms in men (Elovainio et al., 2009). A recent study from a 
largest study to date, reported elevated levels of CRP to be associated with increased 
risk for psychological distress and depression in general population (Wium-An-
dersen et al., 2012).
Concerning the treatment of depression with antidepressants, it was hypothe-
sized that, in particular brain monoamines (serotonin, norepinephrine and dopa-
mine) activity is disturbed in depressed patients (Thase et al., 2002). This theory 
was proved to be true at least in part by the use of imaging techniques (Hirvonen 
et al., 2008). Disturbance in monoamine neural transmission is related to the ill-
ness mechanisms of depression, but only as one factor (Belmaker and Agam, 2008). 
The monoamine hypothesis has advanced into the direction of a chemical or mo-
lecular hypothesis of depression, which suggests that mood disorders are produced 
by long-term changes in the production or activity of molecules e.g. neuropep-
tides, growth factors and their receptors and intracellular signalling molecules in 
the brain (Manji et al., 2001; Castren, 2005). 
Stress activates the hypothalamic-pituitary-adrenal axis through a complex 
mechanism. Key elements of the stress response in the brain as a whole are the hip-
pocampus, the prefrontal cortex and amygdala. In general, hippocampus and pre-
frontal cortex suppress and amygdala stimulates HPA axis activity. Several lines of 
research point to sepa rate mechanisms, for example, amygdala hyperactivity, hy-
poactivity in the DLPFC (the dorsolateral prefrontal cortex) and blunted nucle-
us accum bens response in individuals with depression that increase the salience of 
negative stimuli and decrease the salience of positive or rewarding stimuli. As a re-
sult, a person with depression displays a cognitive bias towards negative informa-
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tion and away from positive information, thus contributing to the maintenance 
of a depressed mood state (Disner et al., 2011). There is a plausible role for cy-
tokines, brain-derived neurotrophic factor (BDNF), and their interaction in major 
depressive disorders (MDD) etiology. The bidirectional relationship between BD-
NF and cytokines is therefore discussed. Cytokines affect the synthesis and reup-
take of serotonine, dopamine, and glutamate. In addition, they interfere neuroplas-
ticity by disturbing groth factors during chronic stress (Capuron and Miller, 2011). 
In short-term, dopamine helps to avoid a stressor, but in long-term, chronic stress 
leads to a reduction in dopamine levels   (Cabib and Puglisi-Allegra, 2012). Poten-
tial ramifications for MDD treatment that are appraised include  use of cytokine 
biomarkers for identifying specific populations for targeted MDD therapy, the use 
of medications that directly antagonize the role of inflammatory cytokines,  poten-
tial indirect modifiers of cytokine activity, and possible downstream intracellular 
second messenger targets (Lotrich, 2012). 
Neuroplasticity may have a key role in the pathophysiology of MDD, a con-
cept supported by experimental studies that found that excessive cortisol secretion 
and/or excessive production of inflammatory cytokines impair neuronal plastici-
ty and neurogenesis in the hippocampus (Frodl et al., 2012). Antidepressant treat-
ment can lead to a normalization of the elevated cytokine levels that occur when an 
individual is suffering from major depression. Most antidepressants have also spe-
cific anti-inflammatory effects (Maes, 2010; Raedler, 2011).
2.4 Comorbidity of MDD
2.4.1 Definition of the concept 
Comorbidity is defined as the occurrence of two or more disorders in a person in 
a defined period of time (Klerman, 1990). The comorbidity concept was first pre-
sented in literature on the epidemiology of medical diseases.  In psychiatry the con-
cept of comorbidity has been sustained by DSM-III and DSM-IV with a multixial 
classification system (APA, 1987). The concept of comorbidity has been discussed, 
whether it refers to co-occurrence, covariation (Lilienfeld, 2003), or multimorbid-
ity (Kessler et al., 1994). 
Comorbidity of depression has been the topic of numerous studies over the 
years (Angst, 1996; Kessler et al., 2003; Pirkola et al., 2005; Olfson et al., 2012). Co-
morbid MDD is so common that it is almost exceptional not to have a comorbid 
disorder in connection with MDD (Kessler et al., 1996). MDD patients have gener-
ally at least one comorbid Axis I disorder (Placidi et al., 2000, Melartin et al., 2002; 
2004; Merikangas et al., 2003; Alonso et al., 2004; Hasin et al., 2005; Vuorilehto et 
al., 2005). In NCS-R, the lifetime prevalence was over 70% and the 12-month prev-
alence ocer 80% of at least one comorbid disorder among MDD patients, including 
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59% with anxiety disorder, 24% with substance use disorder and 30% with impulse 
control disorder (Kessler et al., 2003). Half of the subjects with MDD have a cur-
rent anxiety disorder (Regier et al., 1990; 1998; Kessler et al., 1996b), and about a 
fifth a current substance use disorder (SUD) (Regier et al., 1990; Grant & Harford, 
1995; Kessler et al., 1996a).  In a nationally representative sample of 5958 adults, 
a majority (61.3%) of respondents with MDD reported having sought treatment 
for depression at some point in their lives (Olfson et al., 2012). In the National 
Comorbidity Survey Replication (NCS-R) study about 80% of respondents with 
12-month DSM-IV MDD had at least one axis I comorbid disorder, with anxie-
ty disorders being the most common (67.8%), followed by substance use disor-
ders (27.1%) (Kessler et al., 2003). In the National Epidemiologic Survey on Alco-
hol and Related Conditions (NESARC) study (Hasin et al., 2005) in subjects with 
lifetime DSM-IV MDD, the most common comorbid axis I disorders was any anx-
iety disorder (41.4%), followed by any alcohol use disorder (40.3%). In the Finnish 
Health 2000 study, 32% of respondents with 12-month DSM-IV MDD had at least 
one comorbid disorder, with anxiety disorder being the most common (25%), fol-
lowed by alcohol use disorder (9%) (Pirkola et al., 2005c). 
2.4.2 Comorbidity of MDD in clinical samples
In psychiatric cohorts, the reported prevalences of current comorbid disorders 
among patients with MDD have varied widely. Approximately half of the patients 
have had a current anxiety disorder and about one fifth a current substance use dis-
order (Fava et al., 2000; Zimmerman et al., 2000; Melartin et al., 2002). Dysthymia, 
anxiety disorders, and alcohol use disorders have been significantly more preva-
lent in subjects with MDD than in subjects without MDD (Verhagen et al., 2008). 
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study 
(Rush et al., 2005), which investigated 1376 outpatients of the total population of 
4041, with DSM-IV MDD associated the concurrent comorbidity of MDD with 
other disorders through a Psychiatric Diagnostic Screening Questionnaire. It was 
found that 61.8% of cases having at least one comorbid disorder with social anx-
iety disorder (20.8%) being the most common, followed by GAD (18.8%), OCD 
(13.4%), PTSD (12.4%), bulimia (11.9%), any alcohol use disorder (11.9%), panic 
disorder (11.1%) and agoraphobia (9.4%).  
Clinical studies have reported that comorbidity is one of the major factors as-
sociated with poor MDD outcome as it increases the risk of relapse or recurrence 
(Alnaes & Torgersen, 1997), chronicity (Keller et al., 1984; Mueller et al., 1994), re-
sidual symptoms (Paykel et al., 1995), suicide (Cheng et al., 1997; Fawcett, 1997; 
Foster et al., 1999; Hansen et al., 2003) and psychosocial impairment (Rytsälä et al., 
2005; Lam et al., 2011). 
The reported prevalence of concurrent MDD patients with personality disor-
ders in psychiatric settings has varied greatly (18%-86%): overall, about half of the 
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patients have had a current personality disorder (Melartin et al., 2002). In the Rho-
de Island Methods to Improve Diagnostic Assessment and Services (MIDAS) study 
of 859 outpatients, 51.3% with a current DSM-IV MDD had at least one person-
ality disorder with cluster C disorders being the most common (27.3%), especial-
ly avoidant personality disorder (20.3%), followed by cluster B (14.1%) and cluster 
A (7.3%) (Zimmerman et al., 2005). In a study with depressed outpatients, a sig-
nificant proportion (64%) met criteria for at least one co-morbid personality dis-
order (Fava et al., 2002).  In VDS, 44% of patients with current MDD had at least 
one personality disorder, cluster C personality disorders being the most common 
(32%), followed by cluster A (19%) and B (14%) personality disorders (Melar-
tin et al., 2002). There have been some differences in the prevalences of personali-
ty disorders between primary care and psychiatric care patients. In PC-VDS, 58% 
of DSM-IV MDD patients had a comorbid axis II disorder, cluster B (35%) and C 
(35%) personality disorders being the most common, followed by cluster A (7%) 
personality disorder (Vuorilehto et al. 2005). There are a few studies of the long-
term stability of personality disorders. In a study of 142 outpatients with MDD, 
the 10-year stability of categorical personality disorder diagnosis was found to be 
relatively poor and not higher than that of anxiety disorders (Durbin and Klein, 
2006). However, the relative stability of personality disorder dimensional scores 
was greater than that for categorical diagnosis, generally reaching a moderate lev-
el, and approached the long-term stability of normal-range personality traits. The 
findings from VDS (Melartin et al., 2010) have been similar: the categorical stabili-
ty of concurrent personality disorder diagnoses assigned when the patient was de-
pressed was relatively poor, but the dimensional stability was moderate. 
2.4.3 Physical illnesses comorbidity
MDD increases the risk of developing a number of physical illnesses. The risk is 
not necessarily related to lifestyle, although depression is associated with elevat-
ed prevalence of smoking, alcohol abuse, and lack of physical activity (Herva et al., 
2006; de Wit et al., 2010; Pacek et al., 2012). About 60% of excess mortality is due 
to physical illness (De Hert et al., 2011). Depression increases independently the 
risk of developing coronary heart disease (Hemingway and Marmot, 1999), stroke 
(Everson et al., 1998), osteoporosis (Cizza, 2011), type 2 diabetes (Golden et al., 
2004), and Alzheimer’s disease (Ownby et al., 2006). It will also degrade the prog-
nosis of many diseases. 
2.4.4 Nicotine dependence as MDD comorbidity
The mortality rate of MDD sufferers is double the mortality rate compared to the 
general population (Robson and Gray, 2007). One risk factor is smoking.  MDD 
and nicotine dependence are epidemiologically comorbid. Tobacco smoking is a 
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risk factor for more than 50 diseases, 20 of which are fatal (Lopez et al., 2006). 
Smoking has also been associated with recurrence and even suicidal behaviour in 
depressive subjects (Bronisch et al., 2008). Cigarette smoking and weekly alcohol 
abuse seems to be risk factors for MDD in the general population (Hämäläinen et 
al., 2001). The prevalence of smoking among alcohol-dependent people has been 
found to be 3- to 4-fold that of the general population, at a level of about 80–95% 
reporting smoking (Joseph et al., 1990). Also, a dose-response relationship between 
the number of cigarettes smoked and amount alcohol consumed has been reported 
(Dani and Harris, 2005). In the NESARC study, over one-fifth of patients with cur-
rent nicotine dependence had concurrent alcohol use disorder, mood disorder, and 
anxiety disorder, and nearly one-third had a current personality disorder (Grant et 
al., 2004). In the same study major depression was associated with increased like-
lihood of nondependent cigarette use (Goodwin et al., 2012). In a Finnish study, 
the overall prevalence of smoking was 22.2% in the general population, but 47.5% 
among patients with current alcohol dependence (Pirkola et al., 2006). Substance 
abuse exacts a considerable toll on society in terms of morbidity and mortality, ac-
counting for 21% of deaths, 23% of years of potential life lost, and 8% of hospital-
izations (Single et al., 1999). 
2.5 Treatment of MDD 
Treating subjects with depression remains a major clinical and public health chal-
lenge. Significant  treatment advances have been made recently in the areas of 
pharmacotherapy, psychotherapies, combination of pharmaco- and psychothera-
py, electroconvulsive therapy (ECT) and bright light therapy (Cohen and Guthrie, 
1997; Schulberg et al., 1998; Crismon et al., 1999; Bauer et al., 2002; Bauer et al., 
2002; NICE, 2004; Fochtmann and Gelenberg, 2005; Anderson et al., 2008; Suehs 
et al., 2008; NICE, 2009; Patten et al., 2009; APA, 2010; Suomen Psykiatriyhdistys, 
2010).  Other treatments that have been used for MDD are among others exercise 
(Ernst et al., 2006) and sleep deprivation (Wirz-Justice, 2006). New treatments for 
MDD currently being evaluated include brain stimulation (transcranial magnetic 
stimulation, deep brain stimulation and vagus nerve stimulation) (Eitan and Lerer 
2006; Ressler and Mayberg 2007) and intravenous injection of ketamine (Zarate et 
al. 2006). 
2.5.1 Psychosocial Therapies
In the acute phase, a specific, effective psychotherapy (cognitive, psychodynam-
ic, behavioural, interpersonal, may be provided as an initial treatment for patients 
with mild to moderate MDD (APA, 2010; Suomen Psykiatriyhdistys, 2010). Clin-
ical features that may suggest the use of psychotherapeutic interventions include 
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the presence of psychosocial stressors, intrapsychic conflict/interpersonal diffi-
culties, or comorbid axis II disorder (APA, 2010). There is increasing evidence to 
support the use of a specific psychotherapy in the continuation and maintenance 
phases to prevent recurrences (Nierenberg et al., 2003; APA, 2010; Suomen Psyki-
atriyhdistys, 2010). Frequency of visits usually decreases in the maintenance phase 
(APA, 2010; Suomen Psykiatriyhdistys, 2010). The lack of several randomized, con-
trolled clinical trials of long-term cognitive or psychodynamic psychotherapies, 
or of psychoanalysis makes it difficult to estimate their effectiveness in the treat-
ment of depression. The Canadian CANMAT guideline states that cognitive ther-
apy (CT), cognitive behavioural therapy (CBT), and interpersonal therapy (IPT) 
have efficacy equivalent to that of antidepressants for first-line treatment of mild 
or moderate depression (Patten et al., 2009). 
The combination of psychotherapy and medication is recommended for those 
with psychosocial/interpersonal problems, or comorbid axis II disorder together 
with moderate to severe MDD. Poor adherence to treatments may also warrant a 
combination of treatment modalities (APA, 2010). In a systematic review Pampal-
lona et al. concluded that combined antidepressant therapy and psychosocial treat-
ment is associated with a higher improvement rate than pharmacotherapy alone 
(Pampallona et al., 2004).  
2.5.2 Antidepressant treatment
 
There are three phases of treatment: the acute, continuation and maintenance 
phases. In the acute phase, the aim of the treatment is full remission, in the contin-
uation phase, the prevention of relapse, and in the maintenance phase, the preven-
tion of recurrence (Suomen Psykiatriyhdistys 2010). The most common methods 
of treatments for MDD in Finland are antidepressant treatment with or without 
augmenting and adjunctive medications; psychotherapy and ECT.
Modern effective antidepressant treatment (ADM) has been in use since 1957 
(Ban, 2001) with then the development of new antidepressants being based on the 
monoamine theory. Some types of medication were monoamine oxidase inhibi-
tors (MAOIs) and tricyclic antidepressants (TCAs). More recently developed treat-
ments include agents that block the reuptake of serotonin, noradrenalin or do-
pamine, their names refer to the neurotransmitter systems that they are believed 
to affect the mind the most. The efficacy of ADM has been established in liter-
ally thousands of placebo-controlled clinical trials (Depression Guideline Panel, 
1993). Suitable antidepressant treatment of MDD consists of three phases: an acute 
phase during which remission is induced, a continuation phase, during which re-
mission is preserved and a maintenance phase, during which the vulnerable pa-
tient is protected against recurrence of subsequent episodes (APA, 2010; Suomen 
Psykiatriyhdistys, 2010). The more severe the depression is, the more important 
the antidepressants are for the treatment of MDD. In severe or psychotic depres-
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sion antidepressant treatment is always indicated, whereas in mild or moderate 
cases of depression, effective psychotherapy can be used alone or combined with 
pharmacotherapy. In psychotic depression, the a combination of antidepressants 
and antipsychotics is recommended (Psykiatriyhdistys, 2010). The NICE guideline 
from UK does not recommend antidepressants for mild depression unless other 
treatments have failed (NICE, 2009).
2.5.3 Acute phase treatment and continuation phase treatment
Antidepressant medication is effective in the treatment of the acute depressive ep-
isode and is preventive so long as its use is maintained (APA, 2010).  Acute phase 
pharmacotherapy is effective for all severities of MDE. In mild to moderate depres-
sion, psychotherapy alone or combined with medication is helpful. The more se-
vere the depression, the more important is the role of adequate medication. Ac-
cording to recommendations, adequate dosage of an antidepressant is equivalent 
to imipramine 150–300 mg per day (NICE, 2004) Acute phase treatment lasts for 
weeks or months until remission is reached. The continuation phase should gen-
erally last four to nine months after the induction of remission in order to prevent 
relapses, and after that, maintenance phase treatment should be considered after 3 
or more lifetime episodes to prevent recurrences (Suomen Psykiatriyhdistys 2010). 
2.5.4 Maintenance phase treatment 
MDD is often a recurrent disease and practice guidelines recommend maintenance 
treatment for MDD for most patients with a history of three or more major de-
pressive episodes, comorbid conditions, residual symptoms between episodes, se-
vere disability, suicidal behavior or psychotic features (Depression Guideline Pan-
el, 1993; APA, 2010; Suomen Psykiatriyhdistys, 2010). Maintenance treatment is an 
effective tertiary preventive intervention (Geddes et al., 2003). Maintenance treat-
ment should be nearly the same treatment (antidepressant at full dose, psycho-
therapy perhaps at a lowered frequency) that was effective during acute depression 
and should continue preferably at least for 5 years to prevent further recurrences, 
or in some cases to rest of the life (Depression Guideline Panel, 1993; APA, 2010; 
Suomen Psykiatriyhdistys, 2010). APA defines an indication for maintenance treat-
ment to exist after a major depressive episode among patients having already had 
more than three lifetime episodes but then achieving full remission for more than 
2 months. Treatment should commence 4 months after the achievement of full re-
mission (APA, 2010).
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2.5.5 Other treatment methods
Electroconvulsive therapy (ECT) is the oldest of the modern ways to treat depres-
sion. ECT was first developed 70 years ago as a treatment for psychoses. It has been 
found to be an effective form treatment for severe and psychotic depression and 
should be considered for MDD patients who have medication resistance or when 
rapid relief of depressive symptoms is needed e.g. severe suicidality (Suomen Psyki-
atriyhdistys, 2010). New treatments for MDD currently being evaluated include 
other neurostimulation therapies, deep brain stimulation (DBS), repetitive tran-
scranial magnetic stimulation (rTMS), and vagal nerve stimulation (VNS) (Rush 
et al., 2005; Rossi et al., 2009; Hansen et al., 2011). Of these, rTMS is a safe treat-
ment method with minimal adverse effects with an efficacy resembling that of anti-
depressant medication (Gross et al., 2007). Evidence to support VNS is less robust, 
and deep brain stimulation DBS is still an investigational treatment (Kennedy et 
al., 2009).  Other targets for future agents include N-methyl-D-aspartate (NMDA) 
antagonist ketamine (Zarate et al., 2006), neuropeptide Y, vasopressin V1b, nico-
tinic cholinergic, delta-opiate, dopamine D1, cytokine, and corticotrophin-releas-
ing factor 1 receptors, as well as GABA, intracellular messenger systems, and tran-
scription, neuroprotective and neurogenic factors (Manji et al., 2003; Mann, 2005).
2.5.6 Effects of treatment on brain circuitry 
Both cognitive therapy (CT) and antidepressant medication (ADM) probably af-
fect limbic and prefrontal circuitry, while their proximal mechanisms of action 
might differ (DeRubeis et al., 2008; Disner et al., 2011). The neurobiological under-
pinnings of a blunted response to positive stimuli, a key feature of depression,  has 
been shown in func tional MRI results indicating that nucleus accumbens and pre-
frontal cortex (PFC) activity decreased more dramatically in indi viduals with de-
pression than in healthy controls groups during the period following positive stim-
ulus presentation (Wager et al., 2008; Heller et al., 2009). A primary goal of CT is to 
replace automatic emotional reactivity with more-controlled processing (Rush et 
al., 1982; Heller et al., 2009). ADM might target limbic regions directly rather than 
relying on inhibition though the prefrontal cortex. SSRIs increase the availability 
of serotonin at the synapse, which could lead to inhibition of amygdala as well as 
of other ventral limbic regions, as has been observed in resting-state neuroimag-
ing studies (Mayberg et al., 2000; Fu et al., 2004; Anand et al., 2005; Dunlop et al., 
2012). Treatment likely modifies the effects of illness, e.g. the previously decreased 
volume of amygdala increases with treatment for depression (Fu et al., 2004). CT 
normalizes amygdala and dorsolateral prefrontal cortex (DLPFC) activity in indi-
viduals with depression (DeRubeis et al., 2008).  In addition, antidepressant med-
ication may prevent the reduction of hippocampal volume among patients with 
major depression (Sheline et al., 2003). Using deep brain stimulation to reduce hy-
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peractivity in the subgenual cingulate cortex, thereby reducing bottom-up influ-
ence to some extent, seems to be a promising treatment for depression (Mayberg et 
al., 2005). The evidence shows that CT is as efficacious as antidepressant treatment, 
and that its effects are more enduring. Indeed, it has been proposed that CT helps 
patients learn to recruit prefrontal regulatory brain mechanisms – a skill that these 
patients could continue to use long after treatment ends (Nemeroff et al., 2003; Fu 
et al., 2008). 
2.5.7 Treatment attitudes and adherence
Practice guidelines suggest that psychiatrists should recognize patients’ non-ad-
herence, and encourage them to discuss any concerns regarding adherence (APA, 
2010). Understanding factors influencing attitudes and adherence is important to 
better involve patients in treatment and advance their prognosis. The term “ad-
herence” denotes  the relationship between patient and medical treatment and ad-
vice (Hansen and Kessing, 2007) and has been defined as patient acceptance of rec-
ommended health behaviours (Wright, 1993). The literature (Frank et al., 1992; 
Lingam & Scott, 2002; Nemeroff, 2003) tends to prefer the term adherence instead 
of compliance as it may also remind clinicians to form a good therapeutic alliance 
with the patient, and emphasizes active rather than passive participation of the 
patient in this process. Part of this neglect is explained by the unresolved confu-
sion about terminology, and highly variable methods (i.e. prescription counts, pill 
counts, appointments kept, drug/metabolite plasma concentrations) used in meas-
uring non-adherence (Demyttenaere et al., 2001; Lingam & Scott, 2002; Pampallo-
na et al., 2002; Demyttenaere, 2003). Problems of adherence to pharmacotherapy 
appear similar in both primary care and psychiatric settings, but generalizability of 
findings from one setting to another remains uncertain, and adherence to psycho-
social treatments is largely uninvestigated.  
Medication non-adherence is common; estimates of non-adherence for af-
fective disorders range from 10% to 60%, with a median of 40% (Lingam & Scott, 
2002). Few studies have investigated the extent to which treatment recommenda-
tions, especially after the immediate acute phase, are followed by psychiatric pa-
tients with depression (Simon et al., 2001; Cuffel et al., 2003; ten Doesschate et al., 
2009). Several primary care studies (Katon et al., 1995; Demyttenaere and Haddad, 
2000; Lin et al., 2003; Åkerblad et al., 2006) have reported frequent shortcomings 
such as inadequate follow-up of dosage or monitoring of antidepressant treatment. 
Large register-based studies of primary care patients (Melfi et al., 1998; Claxton et 
al., 2000) also document the marked adverse influence of poor adherence on risk 
of relapse or recurrence. 
However, research on adherence and premature termination of treatment has 
been rare in psychiatric settings. About one-third of depressive patients discontin-
ue their antidepressant treatment during the first month, and nearly one-half by 
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the third month (Olfson et al., 2006); possibly only a quarter of patients use anti-
depressant medication as recommended by international guidelines (Bockting et 
al., 2008). 
Intervention studies have shown that psychoeducation is an effective way to 
enhance treatment adherence by offering structured and detailed information to 
patients about their treatments (Demyttenaere & Haddad, 2000; Lin et al., 2003; 
Vergouwen et al., 2003). Non-adherence undermines optimal treatment and may 
pose a risk for suicidal individuals (Meehan et al., 2006). 
Attitude describes the patient’s subjective opinion of treatment, and is one, 
but not the only, factor influencing adherence. The components of communication 
to patients that have been shown to improve adherence include reminding them 
of when and how often to take the medicine, the need for at least 2-4 weeks before 
beneficial effects may be noticed, the need to take medication even after feeling bet-
ter, the need to consult with the doctor before discontinuing medication, and what 
to do if problems arise (APA, 2010). 
  
2.6 Disability in MDD
2.6.1 Level of functional disability in MDD
Functional disability has been defined as limitations in performing social and fam-
ily roles and tasks (Nagi, 1976), or restricted ability to perform the most basic ac-
tivities. Lack on social adjustment is a part of functional disability. Problems in it 
seem to be difficulties in the patient´s role performance, interpersonal relation-
ships, and work and leisure satisfaction (Weissman and Bothwell, 1976).
2.6.2 Work disability in MDD 
Work disability is a specific form of impairment, defined as inability to work at 
a job or business, and receiving social security benefits in the form of a disabili-
ty pension on that basis. Major depression (MD) is one of the most prevalent psy-
chiatric disorders and a leading cause of loss in work productivity. The risk of dis-
ability is almost five-fold compared to non-depressive individuals (Kessler et al., 
1999). Moreover, high costs are incurred by employees and employers alike (Stew-
art et al., 2003; Katon et al., 2008) and by society as a whole (Kessler et al., 1999; Si-
mon et al., 2000).  Despite this link to public health and the economic importance, 
only a few studies have specifically focused on the granting of such pensions and 
long sick leave to patients with depression (Karpansalo et al., 2005; Bultmann et al., 
2008; Doshi et al., 2008; Korkeila et al., 2010). Of these, most were either record-
based (Rytsälä et al., 2001; Sorvaniemi et al., 2003; Bultmann et al., 2008) or retro-
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spective (Isometsä et al., 2000) and seldom longitudinal (Karpansalo et al., 2005; 
Korkeila et al., 2010). 
In previous studies from general population and primary care settings, dis-
ability pension has been predicted by older age (Karpansalo et al., 2005; Doshi et 
al., 2008), severity of depression (Bultmann et al., 2008), psychiatric comorbidity 
(Korkeila et al., 2010), medical comorbidity (Karpansalo et al., 2005) and person-
ality disorder (Korkeila et al., 2010).  Shortcomings in treatment of depression and 
poor adherence to treatment (Katon et al., 1995; Lingam and Scott, 2002)  have 
been reported to affect recovery from depression, and thus contribute to functional 
and work disability(Von Korff et al., 2003). The longitudinal and recurrent nature 
of MDD makes the need for investigation of long-term predictors obvious. Howev-
er, remarkably few prospective, comprehensive clinical studies on long-term work 
disability in psychiatric or primary care exist.  
2.6.3 Work disability pension due to MDD 
Depression is the most prevalent mental disorder causing sickness absence from 
work on the grounds of illness (Wells et al., 1989; Hensing et al., 2000), and the 
growing number of disability pensions granted for this reason is a major concern. 
Major depressive disorder (MDD) is one of 10 leading diseases in the global bur-
den of disease (Lopez et al., 2006), and by 2030 it is projected to be the main cause 
of disability (WHO, 2004). In many Western countries, disability compensations 
granted for depressive disorders have markedly increased since the 1990s (Järvisalo 
et al., Finland; 2005). The risk of disability is almost five-fold compared to asymp-
tomatic individuals (Kessler et al., 1999). Moreover, high costs are incurred by em-
ployees and employers alike (Stewart et al., 2003; Katon et al., 2008) and by society 
as a whole (Kessler et al., 1999; Simon et al., 2000).  In Finland, almost half of the 
disability pensions were granted due to depression in 2005 (Source of information: 
Finnish Centre for Pensions, 2006).
The scarcity of previous studies on predictors for a disability pension renders 
comparison with previous findings difficult. Although predictors for short-term 
sick leave are not necessarily the same as those disability pension, medium-term 
studies of absenteeism due to illness have reported mostly convergent findings. Se-
verity of depression has been associated with work disability, and working people 
with vulnerable personalities (neuroticism) have a greater risk of impaired work 
functioning, independent of the risk from any mental disorder they may have 
(Kruijshaar et al., 2003; Michon et al., 2008).
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3 Aims  of  the  study
This study investigated the prospective 5-year outcome of a sample of 269 patients 
with DSM-IV MDD in secondary level psychiatric care.
The specific aims of the study were:
I
To investigate in a 5-year prospective follow-up study of psychiatric patients with 
major depressive disorder the prevalence, duration and predictors of maintenance 
treatment.
II
To investigate patients´ attitudes and adherence towards pharmacotherapy and 
psychotherapeutic treatments at baseline, 6 months, 18 months and 5 years.  
III
To investigate factors predicting the granting of a long-term disability pension 
among psychiatric patients with MDD.  
IV
To compare the characteristics of smoking and non-smoking psychiatric MDD pa-
tients and to investigate whether depression and smoking behaviour covary or have 
an independent course.  
39THL – Research 98 • 2013
4 Materials and methods   
4.1 General study design   
The Vantaa Depression Study (VDS) is a collaborative depression project between 
the Department of Mental Health and Substance Abuse Services, Mood, Depres-
sion, and Suicidal Behaviour Unit of the National Institute for Health and Wel-
fare, Helsinki (the former Department of Mental Health and Alcohol Research of 
the National Public Health Institute, Helsinki), and the Department of Psychiatry 
of Helsinki University Central Hospital (HUCH), and Peijas Hospital, Vantaa, Fin-
land.  The Department of Psychiatry at Peijas Hospital (PMCD) provides second-
ary care psychiatric services to all residents of Vantaa (169 000 inhabitants in 1997), 
and provides psychiatric services to all Vantaa citizens. The Ethics Committee of 
Peijas Hospital approved the study on 2nd December 1996 and the 5-year follow-
up study on 23rd January 2002. 
4.2 Screening 
The first phase of patient sampling for the VDS cohort involved screening all pa-
tients in the PMCD with a possible new episode of DSM-IV-TR MDD between 1st 
February 1997 and 31st May 1998. During that period, every patient (N=806) aged 
20–59 years 1) seeking treatment, 2) being referred, or 3) already receiving care 
and now showing signs of deteriorating clinical state in the Department of Psychi-
atry but without a clinical diagnosis of ICD-10 schizophrenia or bipolar I disorder, 
was screened for the presence of depressive symptoms. The screening instrument 
included the five screening questions for depression from the WHO Schedule for 
Clinical Assessment in Neuropsychiatry (SCAN), Version 2.0 (Wing et al., 1990). 
In addition, the Scale for Suicidal Ideation (SSI) (Beck et al., 1979) was also com-
pleted to identify patients with moderate to severe suicidal ideation or plans. After 
receiving either 1) a positive response to any of the SCAN screening questions, or 
2) a score of six or more in the SSI, irrespective of the presence of depressive symp-
toms, the patient was fully informed about the study project, and requested to sign 
an informed consent document. Of the 703 eligible patients, 161 (22.9%) refused 
to participate in the study, but 542 (77.1%) agreed and gave written informed con-
sent. Those who withheld consent did not differ significantly (P>.05) by age or 
gender from those who consented. 
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4.3 Baseline evaluation 
4.3.1 Diagnostic measures
In the second phase of sampling, the 542 participating patients were interviewed 
face-to-face by a researcher using the WHO SCAN 2.0 by interviewers who had 
all received relevant training by a WHO certified training centre. They inspected 
whether or not the current mood episode fulfilled the criteria for (unipolar) DSM-
IV-TR MDD. All psychiatric and medical records in the PMCD, including a stand-
ardized set of laboratory tests, were also available at the interview. Patients current-
ly abusing alcohol or other substances were interviewed after two to three weeks of 
abstinence in order to exclude substance-induced mood disorders. On the basis of 
interviews, 269 patients were diagnosed with DSM-IV MDD and included in the 
study (Figure 1). Diagnostic reliability was examined using 20 videotaped diagnos-
tic interviews; the kappa coefficient for MDD was 0.86 [0.58-1.0] with a 95% ob-
served agreement rate. 
The decision to include the patient in the study cohort was made by the re-
searcher during the interview, after which the entire SCAN interview (Wing et al., 
1990) was conducted to achieve a full picture of axis I comorbid disorders. In addi-
tion, the Structured Clinical Interview for DSM-III-R personality disorders (SCID-
II) (Spitzer et al., 1987; Spitzer et al., 1989) was used to assess diagnoses on axis II. 
Current axis III diseases were measured via a self-report checklist with 44 items 
(corresponding to ICD-10 diagnoses). Only axis III diseases diagnosed by a physi-
cian and currently being treated were included. 
Screening
N=806
Positive
N=703
Consenting
N=542
DSM-IV MDD
N=269
Negative
N=103
Not consenting
N=161
No MDD
N=273
Figure 1.  Flow-chart of the screening process in the Vantaa Depression Study.
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4.3.2 Exclusion criteria  
All patients who had earlier received a diagnosis of DSM-IV-TR bipolar I or II dis-
order, schizoaffective disorder, schizophrenia or another psychotic disorder, organ-
ic or substance-induced mood disorder were excluded from the study, even though 
they fulfilled the symptom criteria of current MDE. Also, patients with a history 
of MDD, not fulfilling the criteria of the disorder in the current episode were ex-
cluded. 
4.3.3 Observer and self-report scales    
The 17-item Hamilton Rating Scale for Depression (Ham-D) (Hamilton, 1960) 
and the 21-item Beck Depression Inventory (BDI) (Beck et al., 1961) were used to 
assess severity of depression, the Scale for Suicidal Ideation (SSI) for suicidal be-
haviour (Beck et al., 1979); the Social and Occupational Functioning Assessment 
Scale for DSM-IV (SOFAS) (Goldman et al., 1992) for functional level; the Inter-
view for Recent Life Events (IRLE) (Paykel, 1983), the Interview Measure of Social 
Relationships (IMSR) (Brugha et al., 1987) and the Perceived Social Support Scale 
Revised (PSSS-R) (Blumenthal et al., 1987) for social support. Self-report scales, in 
addition to the BDI, included the Beck Anxiety Inventory (BAI) (Beck et al., 1988), 
the Beck Hopelessness Scale (HS) (Beck et al., 1974), the Social Adjustment Scale-
Self Report (SAS-SR) (Weissman and Bothwell, 1976), and the Eysenck Personali-
ty Inventory (EPI) (Eysenck and Eysenck, 1964). 
4.4 Follow-up procedure  
4.4.1 Study participants
Of the 269 patients with current MDD initially included in the study (Melartin et 
al., 2002), 229 participated in the 6-month, 207 in the 18-month and 182 in the 
5-year follow-up (Figure 2). The median times of follow-up interviews were 6.5 
and 18.8 months, and 65.2 months from baseline, respectively. The 5-year follow-
up interviews were performed individually by 2 interviewers (I.A.K.H. or K.M.H); 
all available medical and psychiatric records were used to complement the infor-
mation. The average duration of an interview was 2–3 hours and took place in psy-
chiatric outpatient units of Vantaa and HUCH, between April 12, 2002 and April 
30, 2004. By the 18 month mark, 13 patients’ diagnoses had been changed to bipo-
lar disorder; at the 5-year follow-up, 16 patients were diagnosed as having bipolar 
disorder, 1 was diagnosed with schizophrenia, and 2 were diagnosed with schizoaf-
fective disorders. Ten patients had died, one of whom had switched to bipolar dis-
order. Thus, after 5 years, 163 unipolar patients (71.5% of those eligible [n = 228]) 
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remained for the analyses, and 65 patients dropped out. Life-chart information on 
142 of the 163 patients was available for the entire follow-up period.
At baseline, the majority of the 269 patients in the cohort were outpatients 
(83%), females (73%), half (50%) were married or cohabited, and 60% employed 
with a mean age of 39.6 years (SD=11.1). More than a third (35%) was experienc-
ing their first MDD. The patients’ mean Ham-D value was 19.5 (SD=5.9), and BDI 
27.7 (SD=8.6). A majority (79%) suffered from at least one comorbid disorder, and 
over half (54%) had 2 or more. Over half (57%) suffered from a comorbid anxi-
ety disorder, a quarter (25%) from alcohol abuse or dependence, and almost half 
(44%) from at least one personality disorder (Melartin et al., 2002) (Table 1).
At five years, a majority of the patients (N=163) were females, outpatients, 
over half married or cohabited, two thirds employed, two thirds had a comorbid 
axis I disorder, and two fifths an axis II disorder (Table 1). The median 17-item 
Ham-D score was 23.0 for those currently in an MDE. At 5 years, half of the fol-
lowed-up subjects (49.7%, 81/163) were in full remission, i.e. without any signifi-
cant depressive symptoms, and one-fourth (23.9%, 39/163) were currently in the 
midst of MDE.
DSM-IV MDD
N=269
Six months
N=229
18 months
N=207
5 years
N=182
Bipolar N=29
Schizophrenic N=3
Unipolar MDD
N=163
Life-chart from 
entire follow-up       
N=142
Figure 2.  Flow-chart of the follow-up process in the Vantaa Depression Study. 
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Table 1.  baseline characteristics of patients participating to the 5-year follow-up of the 
Vantaa Depression Study (n=163)
Characteristic                                                             N (%) 
Sosiodemographic factors
Sex
   Female 127 (77.9) 
Married or cohabiting         93 (57.1) 
Professional education        60 (36.8) 
Employed 105 (64.4) 
Low income                             64 (39.3)
Recidential area (east Vantaa) 62 (38.0)
Mean (SD)           
Sosiodemographic factors
Age (years) 40.7 (11.3) 
Clinical factors
Age at onset          33.0 (12.7) 
Ham-D                                 18.6 (5.8) 
BDI                                         27.0 (8.6) 
BAI                                          21.3 (10.6)
SOFAS                                    53.5 (9.4)
Hopelessness (HS) 10.2 (4.7) 
Psychosocial and personality factors
Neuroticism a 17.2 (3.7)
Extraversion a 9.8 (4.5)
Size of social network 7.8 (3.6)
Perceived social support (PSSS-R) 39.1 (12.7)
Negative life eventsb 4.0 (11.0)
Clinical factors
Suicidal ideation (SSI) 25th 0.0
50th 0.0
75th 12.0
Number of previous MDEs    0.0
                                    50th 1.0
                                             75th 2.0
n %
Outpatient 143 (87.7)
MDD subtype
  Melancholic                             51 (31.3) 
  Atypical                                    18 (11.0) 
  Psychotic                               7 (4.3) 
Axis I comorbidity       104 (63.8)
Dysthymia 17 (10.4)
n %
Comorbid disorders
Anxiety disorders 89 (54.6)
   Phobic/ Nonphobic 60  (36.8)
   Panic disorder 24
      with/ 9 (5.5)
      without agoraphobia 15 (9.2)
   Agoraphobia without panic 16 (9.8)
   Specific phobia 43 (26.4)
   Social phobia 22 (13.5)
   OCD 7 (4.3)
   GAD 26 (16.0)
Alcohol use disorders 29 (17.8)
  Dependence 11 (6.7)
   Abuse 18 (11.0)
Axis II comorbidity
Personality disorders 66 (40.5)
   Cluster A 26 (16.0)
   Cluster B 21 (12.9)
   Cluster C 46 (28.2)
Mean (SD)
No. of psychiatric disorders (1.6)
Axis III comorbidity
   No. of current somatic diseases (1.2)
a Eysenck Personality Inventory: for dimensions of 
neuroticism and extroversion. 
b Interview for Recent Life Events: objective meas-
ure of negative impact of adverse life events. Ab-
breviations:  Ham--D = Hamilton Rating Scale for 
Depression, BDI= Beck Depression Scale, BAI = 
Beck Anxiety Scale, HS = Beck Hopelessness Scale, 
SSI = Scale for Suicidal Ideation, SOFAS = Social and 
Occupational Functioning Assessment Scale, OCD 
= Obsessive-Compulsive Disorder, GAD = Gener-
alized Anxiety Disorder, PSSS-R = Perceived Social 
Support Scale-Revised.
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4.4.2 Study drop-outs  
The reasons for dropping out (N = 65) from the 5-year follow-up were as follows: 
patients unreachable despite several efforts (33.8%, N = 22), withdrawal of con-
sent (63.1%, N = 41) and patients living too far away (3.1%, N = 2). The dropouts 
were more likely  to have been inpatients (24.6% vs. 12.3%, χ2 = 5.33, df = 1, p = 
.021), were younger (median age = 35.3 vs. 42.3 years, Z = –2.20, p = .028), were 
more likely to be male (36.9% vs. 22.1%, χ2 = 5.28, df = 1, p = .022), were more 
likely to be not married or cohabiting (60.0% vs. 42.9%, χ2 = 5.42, df = 1, p = .020), 
had greater percentages of alcohol dependence (26.2% vs. 6.7%, χ2 = 16.2, df = 1, p 
< .001) and psychotic depression (13.8% vs. 4.3%, χ2 = 6.50, df = 1, p = .011), and 
had a somewhat lower level of functioning (median SOFAS score = 50 vs. 55, Z = 
–2.69, p = .007) than patients included in the 5-year cohort. 
In Cox´s proportional hazards analysis, all the information available for dif-
ferent lengths of follow-up time was used. In this case, only patients not participat-
ing to any of the follow-up interviews were dropped from the study (N=20).  They 
were compared with participants who remained in the study, at baseline young-
er (mean age: 33.0 years [SD=9.1] vs. 40.1 years [SD=11.0]; t=2.81, p=.005), more 
often had dysthymia (35.0% vs. 10.0%; χ2=11.0, df=1, p=.001) and panic disor-
der with agoraphobia (20.0% vs. 6.4%; χ2=4.96, df=1, p=.026), had a lower age at 
onset (mean age: 27.1 years [SD=8.8] vs. 31.8 years [SD=12.7]; t=2.22, p=.035), 
had more antisocial personality disorder symptoms (z=–2.73, p=.006), reported 
less perceived social sup port (t=2.01, p.046), were more often unemployed (70.0% 
versus 37.9%; χ2=7.93, df=1, p=.005), and were less often married or co habiting 
(80.0% vs. 47.4%; χ2=7.87, df=1, p=.005). 
4.4.3 Life-chart methodology
The careful duration of the index episode and the timing of possible relapses/recur-
rences were examined by gathering all available data, which were then combined 
into the form of a graphical life chart. This was created at the six- and 18-month 
interviews after reviewing with the patient all the information from the follow-up 
period. The life-chart was based on DSM-IV criteria and definitions. Time after the 
first baseline interview was divided into three periods: (1) state of full remission 
(none of the 9 MDE criteria symptoms), (2) state of partial remission (1–4 of the 9 
symptoms), or (3) state of MDE (5+ of the 9 symptoms). Patients were considered 
to have achieved full remission if they had spent at least two consecutive months 
in the state of full remission, and partial remission if they had spent at least two 
months in the state of partial remission. Relapse was defined as a return of symp-
toms fulfilling the DSM-IV criteria for MDE after a period of less than two months 
(but more than 2 weeks) with symptoms below the MDE threshold. Recurrence 
was defined as in the DSM-IV definition for 296.3x MDD, as a return of symp-
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toms sufficiently severe to satisfy criteria for an MDE after at least two consecutive 
months of partial or full remission.
4.4.4 Outcome measures 
After baseline, the patients were asked to complete the BDI monthly for six months. 
The outcome of MDD and the comorbid disorders was investigated at six and 18 
months by SCAN 2.0 and SCID-II interviews. In the 5-year follow-up, the SCID-
I for DSM–IV–TR Axis I Disorders (First et al., 2002) was used instead of SCAN. 
Besides that, all observer- and self-report scales were included at follow-up assess-
ments. All available medical and psychiatric records were used to complete and 
check the in terview information. The diagnoses and timing of depressive episodes 
were based on the structured interviews as well as patient records.
4.4.5 Treatment received
All available data from interviews and medical records was used in analyses includ-
ing psychopharmacological treatment, number of visits to psychiatrists and other 
health professionals, inpatient treatment, and acceptance or refusal of antidepres-
sant treatment. All antidepressant trials and their doses were recorded as well as 
the adequacy of the antidepressant treatment trials and their doses. Other medica-
tions, like antipsychotics, anxiolytics, hypnotics, and possible augmentation med-
ications, and received electroconvulsive therapy were recorded. Psychosocial treat-
ment was investigated regarding its type, length, and the number of visits. 
At baseline, most patients (88%) received antidepressants, and, for the major-
ity (78%), the dosage was adequate for the acute phase. More than half (57%) re-
ceived selective serotonin reuptake inhibitors (SSRIs) alone at baseline, about one 
fifth (18%) received newer antidepressants (tetracyclics, serotonin-norepineph-
rine reuptake inhibitors SNRI, RIMA reversible inhibitors of monoamine oxidase), 
only 8% received tricyclic antidepressants (TCAs), and 6% received combination 
treatment, usually an SSRI and a TCA. Nearly all patients (98%) received psycho-
therapeutic support in the early acute phase, but only few had weekly psychother-
apy (16%) (Melartin et al., 2005). 
At 5 years, 49.7% (N = 81) of the patients did not receive any treatment. One 
fourth (24.5%, N = 40) were currently receiving psychosocial treatment, 15.3% 
(N = 25) were receiving psychotherapeutic support, and 9.2% (N = 15) weekly 
psychotherapy. Nearly half (44.8%, N=73) were currently using an antidepressant. 
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4.4.6 Patients’ attitudes towards treatments
Attitudes towards antidepressant and psychotherapeutic treatments at baseline 
were assessed separately by interview and rated on an ordinal scale with the fol-
lowing items: patient 1) actively wants treatment, 2) passively accepts treatment, 3) 
has reservations about treatment, 4) definitely has negative attitudes towards treat-
ment, or 5) could not answer. At the follow-ups, patients were interviewed with 
scales comprised of the following items: attitudes are 1) very positive, 2) positive, 3) 
neutral, 4) negative, 5) very negative towards treatment, or 6) could not answer. Pa-
tients with reservations about, or definitely negative attitudes towards treatments 
were also asked their subjective reasons for these attitudes, with the following al-
ternatives: 1) generally negative attitudes toward treatment, 2) fear of side-effects 
(antidepressants) / not wanting to confide in a stranger (psychotherapeutic treat-
ments), 3) fear of dependence, 4) not knowing enough about treatment, 5) pa-
tient’s / other’s negative earlier experiences of treatment, 6) negative information 
from the media, 7) no belief that treatment will help, 8) treatment too expensive, 
or 9) could not answer.
4.4.7 Self-reported treatment adherence
Self-reported treatment adherence concerning the treatments provided was inves-
tigated by repeatedly  interviewing patients at the follow-ups using an ordinal scale 
with the following response items: has the patient come to sessions/been on anti-
depressants 1) regularly, treatment compliance adequate with respect to treatment 
goals, 2) somewhat irregularly, it is unclear whether this would affect treatment 
goals, 3) very irregularly, the treatment did not proceed according to plan, and 4) 
not at all, the provided treatment could not be implemented.
4.4.8 Sosio-demographic characteristics and work status
Patients’ age, gender, marital status, occupational status, work status and both the 
beginning and at the end of the treatment period were noted and especially work 
disability pensions. Current work status and length of sick-leave (granted by a phy-
sician) were recorded at every interview point. These were based on patients’ self-
reports and the medical records in use at interview.
4.4.9 Information on disability pensions
Information on disability pensions granted to subjects belonging to the VDS pop-
ulation was obtained from interviews, patient records, and registers of the Social 
Insurance Institution of Finland for the 2002–2007 period. Based on all available 
information, dates on the granted pension events were recorded in the patient’s 
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life-chart. When this research was carried out, in Finland, sick leaves due to depres-
sion and lasting over two months were mostly granted by psychiatrists. These usu-
ally occur as several consecutive sick leave periods during treatment, if the patient 
is considered incapable of working. Medical certificates issued by a psychiatrist for 
work disability allowances are referred to and granted by the Social Insurance Insti-
tution of Finland. After receiving this daily allowance from sickness insurance for 
300 days (calculated on the basis of a six-day working week), employees aged 63 to 
65 years become eligible for a disability pension. Medical certificates are referred to 
and pensions granted by the pertinent insurance company with which the person 
in question is entitled to pension insurance benefits. The information on a possible 
disability pension from the Social Insurance Institution of Finland was obtained 
for the whole study population cohort, except for two subjects who withdrew their 
consent regarding pension register information.
4.4.10 Smoking behavior
The information on smoking behaviour was studied on self-reported material at 
the follow-up interviews, using a scale with the following response items: the pa-
tient 1) has never smoked, 2) has quit smoking, 3) has smoked occasionally, or 
4) has smoked regularly. The number of cigarettes per day was recorded. We re-
quired that information on smoking status from at least three follow-up interviews 
would be available. Thus, information on 214/269 patients (79.6%) was includ-
ed in the analyses of smoking behaviour and depression. Those dropped from the 
study were subjects who did not participate in any follow-up (n=20) or for whom 
information on smoking was available from only one or two time-points. 
4.5 Statistical methods   
Study I 
Chi-square test (with Yates` correction), Fisher`s exact, Mann-Whitney and 
Kruskal-Wallis tests, and the two-sample t-test were used when appropriate. Lo-
gistic regression was used to investigate predictors for receiving maintenance treat-
ment from a predetermined set of twelve predictors covering different domains. 
The nonsignificant variables were eliminated from the final model, but in it age, 
gender and length of maintenance indication (months) were taken into account. 
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Study II 
Friedman´s and Cochran´s tests were used for analyses of changes in attitudes and 
adherences during the follow-up. Univariate and multivariate logistic regression 
models were used to evaluate attitude and adherence to treatment in the final fol-
low-up interview; positive and negative outcome values were compared. Respons-
es of “not having received the treatment” or “not being able to answer” were exclud-
ed from the analyses. In these analyses, censored data included subjects who left the 
study before any follow-up interview. The baseline attitude towards treatment was 
added to the model when analysing adherence.  
Study III
Normally distributed continuous variables were analysed by the two-sample t-test 
or by ANOVA test, and non-normally distributed variables were analysed using the 
Mann-Whitney and the Kruskal-Wallis tests.   Kaplan-Meier survival curves were 
used to estimate the probability of a granted disability pension during the 5-year 
follow-up. Cox proportional hazards models were used for univariate and multi-
variate analyses to predict the interval time to the date the pension was granted. 
Subjects were eliminated from the survival analysis at the time they discontinued 
the study, i.e. either at the time of the last interview or due to change of diagnosis. 
Study IV
Multivariate methods were used to control for possible confounding factors, and 
these analyses constitute our main findings. Discriminant analyses were used for 
a linear combination of predictor variables that would maximally separate two 
groups of interest (never smoked, has smoked) from one another. Smoking was 
similarly operationalized in logistic model as a three-category ordinal variable at 
each time point (does not smoke, smokes occasionally, smokes regularly). For dis-
criminant analyses, a predictor “number cigarettes per day” was used. Whenev-
er the predicted variable in a regression equation was categorical (smoking, alco-
hol use disorder), the relationship between the predictor and the predicted variable 
was to be interpreted as a logistic regression. When the Ham-D measure for de-
pression was used, this path was interpreted as a classical regression path. Mplus 
5.21 was used to estimate the models (Muthén and Muthén, 1998–2010).
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5.1 Maintenance pharmacotherapy in MDD  
          (Study I)
5.1.1 Maintenance treatment received
Figure 3 summarizes the maintenance treatment patients received up to the 5-year 
follow-up. Only about half of the patients (57.0%, 49/86) received the treatment 
indicated by their diagnosis and only for 15.9% (SD ±43.7) (of all patients with 
indication) of the total time (2961.4 patient months) with indication, for a mean 
of once (SD ±0.71).  Median time with indication was 22.7 months (SD±17.7), 
and median duration of maintenance treatment received was only 2.8 months 
(SD±14.8). Patients receiving maintenance treatment visited physicians more often 
than those not receiving such treatment (median 4.0 [SD±5.72] vs. 2.0 [SD±2.78], 
z=-2.65, p=0.008), among whom in two thirds of cases (64.9%, 24/37) contact with 
secondary care services had ended prior to the onset of indication. 
Figure 3. Proportion of patients and time with maintenance antidepressant treatment dur-
ing five-year follow-up of Vantaa Depression Study (VDS).
Maintenance treatment
No maintenance treatment
Patients with 
maintenance treatment
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5.1.2 Predictors for maintenance treatment received
Maintenance treatment associated significantly with numbers of previous epi-
sodes, of comorbid Axis I-III disorders and mental disorders, severity of anxie-
ty, anxiety disorders, panic disorder, social phobia, avoidant personality disorder, 
positive medication attitude, good adherence during the acute phase, and higher 
income level (Table 2).  However, in multivariate logistic regression analyses, only 
good antidepressant adherence in the acute phase (OR=3.18; 95% CI 1.12 – 9.03, 
p=0.030) independently predicted maintenance treatment. 
5.2 Treatment attitudes and adherence in MDD  
           (Study II)   
5.2.1 The general features of treatment attitudes and adherence 
during follow-up
During follow-up, treatment adherence was reportedly good, and the overall atti-
tudes to both antidepressant medication and psychosocial treatment were positive. 
Among study cohort patients, attitudes to antidepressant medication became less 
positive during the follow-up (χ2=14.9, df=3, P=0.002), but adherence to medica-
tion did not change significantly.  Attitudes to psychosocial treatment also changed 
to less positive during follow-up (χ2=13.1, df=3, P=0.004), but adherence im-
proved significantly (χ2=6.87, df=2, P=0.032) (Figures 4 a and 4 b). 
5.2.2 Attitudes towards treatments  
During follow-up, nearly four-fifths (78.7%, n=237/187), had a positive attitude 
towards medication and the majority (90.7%, n=227/206) had a positive attitude 
towards psychosocial treatment. Patients with negative attitudes to medication 
were significantly more often female, had fewer previous MDEs, less social pho-
bia, less alcohol dependence, fewer cluster C personality disorder symptoms and 
less comorbid psychiatric disorders, and were more often employed. In multivari-
ate logistic regression models, the predetermined covariates consisted of age, gen-
der, time at risk, number of previous episodes, Ham-D, BAI, SSI, SOFAS, axis I 
disorders, personality disorders, melancholic depression, professional education, 
employment situation, negative life events and neuroticism. Only employment at 
baseline predicted a positive attitude (Table 3).  
51THL – Research 98 • 2013
5 Results
Table 2. Characteristics of major depressive disorder (MDD) patients in the Vantaa Depres-
sion Study with an indication of maintenance antidepressant treatment.
Mainte-
nance (n=49)
No mainte-
nance (n=37)
Total (n=86)
Variable n %  n % n %  χ2 p-value
Sociodemographic features
Female 36 73.5 26 70.3 62 72.1 0.11 0.740
Outpatient status at baseline                 40 81.6 31 83.8 71 82.6 0.07 0.800
Married or cohabiting 33 67.3 18 48.6 51 59.3 3.05 0.081
Comorbid disorders
Axis I disorders 36 73.5 22 59.5 58 67.4 1.88 0.170
Anxiety disorders 33 67.3 17 45.9 50 58.1 3.97 0.046
Alcohol use disorders 12 24.5 8 21.6 20 23.3 0.97 0.755
Axis II disorders 27 55.1 16 43.2 43 50.0 1.19 0.280
MDD subtype features
Melancholic 20 40.8 14 37.8 34 39.5 0.08 0.780
Psychotic 3 6.1 3 8.1 6 7.0 0.13 0.720
Treatment-related factors
Positive attitude towards 
antidepressants 38 77.6 19 51.4 57 66.3 6.48 0.011
Good adherence to 
antidepressantsa 33 71.7 14 45.2 47  61.0 5.50 0.019
mean SD mean SD mean SD t/z p-value
Sociodemographic features
Age 40.1 10.9 37.7 11.5 39.1 11.2 -0.98 0.329
Clinical features of MDD
Age at onset 27.3 12.8 26.9 12.3 27.1 12.6  -0.14 0.888
Number of previous episodes  3.1 3.1  2.5 3.6 2.9 3.3 -2.04 0.041
Ham-D 19.1 5.8 18.9 5.9 19.1 5.8 0.18 0.859
BDI, mean 27.3 7.1 29.0 8.4 28.0 7.7 1.04 0.302
BAI, mean 23.8 10.7 18.9 9.4 21.7 10.4 -2.23 0.029
SOFAS, mean 52.7 9.9 49.6 10.6 51.3 10.3 -1.40 0.166
Comorbid disorders
No. of psychiatric disorders 3.7 2.1 2.9 1.7 3.3 2.0 -1.91 0.059
No. of current somatic diseases 0.8 1.4 0.4 1.0 0.6 1.1 -1.73 0.084
No. of all axis I-III disorders   4.5 2.5 3.2 1.9 3.9 2.3 -2.58 0.012
Psychosocial factors 
Size of social network 7.8 3.7 6.5 3.4 7.3 3.6 -1.66 0.100
Family net income/month (FIM) 9 681 6 029 7 192 4 091 8 692 5 453 -2.01 0.048
Treatment-related factors
Length of maintenance 
indication 40.2 18.1 26.7 20.2 34.4 20.1 -3.25 0.002
Chi square-, t- and Mann-Whitney U-tests.
aInvestigated at 6 months (n=77 due to nine patients missing this interview)
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Figure 4 a. Change of attitudes towards treatment during five-year follow-up in 
the Vantaa Depression Study.
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Figure 4 b. Change of treatment adherence during five-year follow-up in the Vantaa 
Depression Study.
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Table 3.  Predictors of positive vs. negative treatment attitudes and good vs. poor adher-
ence at last follow-up interview of the Vantaa Depression Study (VDS) 
Predictors          OR 95% CI p
Attitude to antidepressants          
   Employed  1.97 1.01 – 3.83 0.046
Pharmacotherapy adherence
   Size of social network 1.11  1.00 – 1.23 0.042
Attitude to psychosocial treatment                           
   No. of cluster B personality disorder symptoms 0.82 0.70 – 0.96 0.012
   No. of cluster C personality disorder symptoms 1.30 1.09 – 1.54 0.003
Psychosocial treatment adherence
    No. of cluster B personality disorder symptoms 0.83 0.72 – 0.95 0.007
    Living alone 3.13  1.10 – 9.09 0.032
Multivariate logistic regression models, adjusted for sex and age.
During the 5-year follow-up, nine-tenths, the majority of patients (n=206, 
90.7%), had at their last follow-up a positive attitude towards psychosocial treat-
ment. Negative attitudes towards psychosocial treatment were significantly associ-
ated with phobia, panic disorder without agoraphobia, cluster C personality dis-
order symptoms, comorbid axis I-III disorders and neuroticism. In multivariate 
logistic regression models,  predetermined covariates included were age, gender, 
time at risk, number of previous MDEs, comorbid axis I-III disorders, Ham-D, 
melancholic depression, employment situation, income level and neuroticism. In 
the models, a higher number of cluster C symptoms predicted a positive attitude 
and a higher number of cluster B disorder symptoms predicted a negative attitude 
(Table 3). 
5.2.3 Adherence to treatment
 
During the 5-year follow-up, the majority (73.6%, 173/128) of patients reported 
good adherence to medication, and to psychosocial treatment (81.1%, 163/133). 
The factors explaining poor adherence to antidepressant medication were eco-
nomic reasons (n=4, 10%), a generally negative attitude towards pharmacotherapy 
(n=5, 12.5%), lack of motivation for pharmacotherapy (n=19, 47.5%), side-effects 
(n=7, 17.5%) and other reasons (n=5, 12.5%) such as fear of addiction, memory 
difficulties and alcohol-related problems (subjects could report several reasons). 
Subjects with poor medication adherence had significantly fewer previous MDEs, 
more often melancholic depressive features, and a smaller social network and at 
baseline a more negative attitude towards medication. According to multivariate 
logistic regression models, the predetermined covariates consisted of age, gender, 
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time at risk, attitude at baseline, number of previous episodes, Ham-D, BAI, SSI, 
SOFAS, axis I disorders, personality disorders, melancholic depression, size of so-
cial network and employment situation. In the analyses, only a larger social net-
work at baseline predicted good adherence (Table 3). 
The factors explaining poor adherence to psychosocial treatment were as fol-
lows: a generally negative attitude towards this treatment form (n=2, 10.5%), a 
lack of motivation (n=9, 47.4%), a practical excuse (n=3, 15.8%) and other rea-
sons (n=5, 26.3%), e.g. poor cooperation or conflict with the therapist. Patients 
with poor psychosocial treatment adherence had significantly more alcohol use 
disorders and cluster B personality disorders and symptoms. In multivariate lo-
gistic regression analyses, the included covariates consisted of age, gender, time at 
risk, negative attitude at baseline, number of previous episodes, Ham-D, BAI, ax-
is I disorders, personality disorders, melancholic depression, size of social network, 
marital status and employment situation. A large number of cluster B personali-
ty disorder symptoms predicted poor adherence and living alone good adherence 
(Table 3). 
5.3 MDD and work disability (Study III)
The information of 230 patients belonging to the labour force at baseline was in-
cluded in the analyses. During the 5-year follow-up, 20 per cent of the patients were 
granted disability pension, and nearly all of them, (95.7%, [44/46]) on the grounds 
of major depression as the primary diagnosis. One patient had depression as a sec-
ondary diagnosis, and one a physical condition (low back pain) as the primary di-
agnosis.
5.3.1 Differences between patients with and without a disability 
pension         
Those patients who were granted a disability pension were significantly older, had 
received vocational education less often, had higher introversion and less perceived 
less social support compared to those not superannuated.  They also were older at 
the onset of depression, had more severe anxiety (in BAI), more comorbid somatic 
disorders, and spent a longer time in MDEs during follow-up than individuals who 
were not granted pension. In addition, they had lower levels of overall social and 
occupational functioning (SOFAS), and were concurrently on sick leave and per-
ceived themselves to be unable to work markedly more often than their non-pen-
sioned counterparts (Table 4). 
Numerous other variables also individually predicted the granting of a disa-
bility pension. These included sociodemographic factors (lack of vocational edu-
cation), clinical and depression-related factors (longer time in MDE prior to entry, 
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Table 4.
Characteristics of subjects pensioned (N=46) or not pensioned (N=184) in the Vantaa 
Depression Study, 5-year follow-up  
                     Not pensioned   Pensioned Total
Characteristic                                                                                                       n  (%)                   n (%)                 n (%)             p
Sociodemographic characteristics                                                                  
Female 136  (73.9) 36 (78.3) 172 (74.8) 0.544
Married or cohabiting         90  (48.9) 0 (65.2) 120 (52.2) 0.048
Vocational education       120  (65.2) 0 (43.5) 140  (60.9) 0.007
Employed 119  (65.4) 6 (57.8) 145 (63.9) 0.342
Low income                             80  (47.6) 3 (34.2) 93 (45,1) 0.134
Clinical characteristics
Outpatient                             155  (84.2) 38 (82.6) 193 (83.9) 0.788
Melancholic                             67  (36.4) 17 (37.0) 84 (36.5) 0.945
Atypical                                    17  (9.2) 3 (6.5) 20 (8.9) 0.559 
Psychotic                           16  (8.7) 3 (6.5) 19 (8.3) 0.632
Axis I comorbidity                                                    
   Any axis I comorbidity                                                    128  (69.6) 28 (60.9 156 (67.8) 0.259
   Dysthymia 15 (8.2) 6 (13.0) 21 (9.1) 0.303
   Any anxiety disorder 107 (58.2) 24 (52.2) 131 (57.0) 0.464
   Any alcohol use disorder                                       47 (25.5) 8 (17.4) 55 (23.9) 0.246
Axis II comorbidity
    Any personality disorder                 76 (41.3) 24 (52.2) 100 (43.5) 0.183 
    Cluster A 35 (19.0) 8 (17.4) 43 (18.7) 0.800
    Cluster B 26 (14.1) 7 (15.2) 33 (14.3) 0.851
    Cluster C 55 (29.9) 19 (14.3) 74 (32.2) 0.138
Perceived work ability
     Good 25 (13.7) 12 (4.4) 27 (11.9) 0.001
     Impaired 111 (61.0) 19 (42.2) 130 (57.3)
     Unable to work 46 (25.3) 24 (53.3) 70 (30.8)
Sick leave at baseline 34 (27.9) 22 (51.2) 56 (33.9) 0.006
Mean (SD) Mean (SD) Mean (SD) p
Sociodemographic characteristics                                                                  
Age (years) 37.5  (10.4) 46.3  (10.3) 39.3 (10.9) <0.001
Clinical characteristics 
Age at onset         30.2  (12.0) 36.9  (13.2) 31.6 (12.5) 0.001
Number of episodes prior to baseline 1.4   (2.5) 2.2  (3.6) 1.6 (2.7) 0.194
Ham-D                                 19.0  (6.5) 20.8  (4.5) 19.4 (6.2) 0.087 
BDI                                         27.2  (8.6) 28.7  (8.5) 27.5 (8.6) 0.281
BAI                                        21.8  (11.0) 25.3  (10.2) 22.5 (10.9) 0.050
Hopelessness (HS) 9.9 (4.9) 10.6 (4.4) 10.1 (4.8) 0.346
Suicidal ideation (SSI) 6.1 (8.0) 5.7 (7.7) 6.0 (7.9) 0.767
SOFAS                                    53.1  (11.2) 49.8  (9.6) 52.5 (10.9) 0.070
Neuroticism* 12.6  (5.6) 16.4  (4.3) 13.5 (5.6) 0.835
Extraversion* 12.3    (4.5) 9.0   (3.1) 11.5 (4.5) 0.003
No. of comorbid psychiatric disorders 3.0 (1.7) 3.2 (2.1) 3.1 (1.8) 0.538
No. of comorbid somatic disorders 0.4 (0.8) 1.1 (1.7) 0.6 (1.1) 0.018
No. of comorbid psychiatric and 
somatic disorders 3.5 (1.9) 4.3 (2.7) 3.6 (2.1) 0.053
Body mass index 24.4 (4.8) 25.8 (5.2) 24.7 (4.8) 0.082
Proportion of time spent in MDE during 
follow-up 0.2 (0.3) 0.4 (0.4) 0.3 (0.3) <0.001
Sociodemographic characteristics                                 
Perceived social support 40.7 (12.2) 36.4 (12.3) 39.9 (12.3) 0.031
Size of social network 7.8 (3.5) 7.2 (3.5) 7.6 (3.5) 0.297
* Eysenck Personality Inventory, neuroticism and extraversion at lowest Ham-D during the follow-up
Abbreviations:  MDE = Major Depressive Episode, Ham-D = Hamilton Rating Scale for Depression, BDI= Beck 
Depression Scale, BAI = Beck Anxiety Scale, SOFAS = Social and Occupational Functioning Assessment Scale.
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severity of depression and anxiety, lower levels of social and occupational func-
tioning), comorbidity (number of comorbid psychiatric and somatic disorders), 
personality (neuroticism, introversion), and psychosocial factors (lack of perceived 
social support). However, besides older age only a perceived lack of work ability 
and greater introversion persisted as independent robust predictors in the multi-
variate analyses. When the proportion of time spent depressed during the follow-
up was added to the model, it was a robust strong predictor together with older age, 
number of comorbid somatic disorders, and lack of vocational education (Table 5). 
A patient’s age had a great effect on the risk of being superannuated: an effect 
which was considerably greater in older age groups. One half (23/45, 51.1%) of pa-
tients > 50 years were granted a disability pension, compared to only one eighth 
(23/185, 12.4%) of those ≤ 50; the relationship between age and risk of being su-
perannuated was nonlinear (Figure 5). Those over 50 did not differ in regard to the 
duration or severity of depression or for the overall level of functioning compared 
to younger age groups. 
Table 5. baseline and 5-years follow-up predictors of granted work disability pension for 
employed patients with major depressive disorder (MDD) in the Vantaa depression study. 
Baseline predictors*                                                                                HR 95% CI P
Age over 50                                                                                    3.91 2.02–7.52 <0.001
Gender (Female)                                                                      1.37  0.66–2.83 0.400
Lower perceived work ability                                                      2.14 1.22–3.76 0.008
Intraversion **                                                                               1.08  1.00–1.16 0.049
Predictors by follow-up***                                         OR                        95% CI  P
Age over 50                                                                                   6.25 2.71–14.3 <0.001
Gender (Female)                                                                             1.01  0.41–2.50 0.988
Proportion of time spent depressed                     14.6 4.43–48.4 <0.001
Number of comorbid somatic disorders         1.47 1.08–2.00 0.013
Lack of vocational education                                                       2.38 1.08–5.2  0.032
*Cox proportional hazards models; analyses adjusted for gender; hazard reported for decreasing time 
to event.
** Eysenck Personality Inventory at baseline.
***Logistic regression models
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Figure 5. Proportion of patients with granted disability pension in relation to age, per-
ceived work ability, and being on sick leave at baseline in the Vantaa Depression Study, 
5-year follow-up.
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Table 6. baseline patient characteristics and smoking status in the Vantaa Depression 
Study during 5-year follow-up (n=214)
Smoking status                                              Never  
smoked  
Intermittent 
smoking      
Regular 
smoking
                                                                                n (%) n (%) n (%) P
59 (27.6) 88 (41.1) 67 (31.3)
Characteristic
Sociodemographic factors
  Female 46 (78.0) 62 (70.5) 50 (74.6) 0.588
 Married or cohabiting 31 (52.5) 49 (55.7) 36 (53.7) 0.928
  Employed 32 (56.1) 61 (70.1) 39 (60.9) 0.207
  Professional education 23 (39.0) 36 (40.9) 25 (37.3) 0.901
  Low income 27 (51.9) 48 (59.3) 32 (52.5) 0.622
  Outpatient 49 (83.1) 79 (89.8) 51 (76.1) 0.074
MDD subtype
  Melancholic 20 (33.9) 32 (36.4) 27 (40.3) 0.751
  Atypical 5 (8.5) 11 (12.5)  4 (6.0) 0.370
  Psychotic 4 (6.8) 6 (6.8)  4 (6.0) 0.974
Axis I comorbidity
  Dysthymia 6 (10.2) 7 (8.0) 9 (13.4) 0.538
  Any anxiety disorder 35 (59.3) 51 (58.0) 33 (49.3) 0.444
  Alcohol use disorder 5 (8.5) 19 (21.6) 24 (35.8) 0.001
    abuse 3 (5.1) 11 (12.5) 7 (10.4) 0.326
    dependence                                                    2 (3.4) 8 (9.1) 17 (25.4) <0.001
5.4 MDD and smoking (Study IV)  
5.4.1 Prevalence of smoking
 
Information on 214 (79.6%) of the 269 patients was included in the analy-
ses. Over the 5-year follow-up, 31.3% (67/214) of the patients smoked regular-
ly, 41.1% (88/214) had intermittent smoking behaviour, and 27.6% (59/214) had 
never smoked. Of the patients not smoking at baseline (50.9%, 109/214), ten 
(9.2%, 10/109) began to smoke, and of patients initially smoking regularly (39.7%, 
85/214), ten (11.8%, 10/85) quit smoking during the follow-up. 
5.4.2 Clinical and socio-demographic characteristic of the sample
Compared with non-smoking patients, patients smoking regularly  had more often 
comorbid alcohol use disorders and a lower age at onset, Cluster B and C personal-
ity disorder symptoms, higher Ham-D score, higher SOFAS score, lower perceived 
social support, smaller social network, higher neuroticism, and had more often at-
tempted suicide prior to baseline. In addition, there was a non-significant tenden-
cy to be younger (Table 6). 
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Axis II comorbidity
  Any personality disorder 19 (32.2) 43 (48.9) 31 (46.3) 0.116
  Cluster A 8 (13.6) 20 (22.7) 12 (17.9) 0.369
  Cluster B 3 (5.1) 14 (15.9) 13 (19.4) 0.056
  Cluster C 12 (20.3) 35 (39.8) 21 (31.3) 0.046
Clinical factors
Suicide attempt prior to baseline 13 (22.0) 26 (29.5) 40 (52.2) 0.001
Suicide attempt during follow-up 8 (13.6) 10 (11.4) 12 (17.9) 0.505
Mean (SD) Mean (SD) Mean (SD) P
Sociodemographic factors
  Age 43.7 (11.4) 39.3 (11.5) 40.2 (9.6) 0.052
Clinical factors
Age at onset 36.6 (13.5) 30.9 (12.4) 30.4 (11.8) 0.006
No. of episodes prior to baseline 1.9 (3.4) 1.6 (2.4) 1.8 (2.9) 0.838
Ham-D 18.7 (6.4) 18.4 (6.0)  20.9 (5.6) 0.027
BDI 25.5 (8.8) 27.6 (7.7) 28.8 (8.3) 0.083
BAI  20.2 (10.3) 22.7 (10.1) 22.3 (11.5) 0.360
Hopelessness 9.1 (4.4) 10.6 (4.7) 10.2 (4.5) 0.147
Suicide ideation (SSI) 5.3 (7.8) 6.3 (7.5) 6.5 (8.3) 0.639
SOFAS 52.1 (10.9) 54.2 (10.3) 49.7 (10.5) 0.032
No. of recurrences  1.6 (1.5) 1.8 (1.8) 1.9 (1.8) 0.665
Time spent in MDEs 9.4 (11.9) 12.0 (15.2) 9.7 (11.3) 0.443
Comorbidity
  Cluster A symptoms 1.9 (2.3) 2.5 (2.9) 2.8 (2.5) 0.195
  Cluster B symptoms 2.3 (2.6) 3.4 (3.3) 4.6 (4.1) 0.001
  Cluster C symptoms 4.6 (3.5) 6.7 (5.0) 6.4 (4.2) 0.016
  No. of psychiatric disorders 2.6 (1.6) 3.2 (1.8) 3.2 (1.9) 0.122
  No. of somatic disorders 0.9 (1.5) 0.6 (1.1) 0.3 (0.5) 0.014
Psychosocial and personality factors
  Perceived social support 42.9 (11.3) 37.5 (13.1) 38.9 (13.0) 0.040
  Size of social network 8.7 (3.7) 8.0 (3.6) 6.2 (3.0) <0.001
  Neuroticisma 12.2 (4.9) 15.0 (5.4) 13.0 (5.7) 0.010
  Extraversiona 10.9 (4.2) 11.3 (5.7) 11.9 (4.3) 0.412
  Adverse life eventsb 7.7 (4.6) 8.1 (4.7) 9.2 (4.5) 0.163
Statistical methods:
Categorical variables: Chi-square test with Yates continuity correction, or Fisher´s exact test 
when the expected cell count was less than 5.
For continuous variables: ANOVA for normal distribution, and Mann-Whitney and Kruskal-
Wallis tests for non-normal distribution.    
aEysenck Personality Inventory: for dimensions of neuroticism and extraversion (at lowest 
Ham-D),
bInterview for Recent Life Events: objective measure of negative impact of adverse life 
events.
Abbreviations:  MDE = Major Depressive Episode, Ham-D = Hamilton Rating Scale for De-
pression, BDI= Beck Depression Scale, BAI = Beck Anxiety Scale, SOFAS = Social and Occupa-
tional Functioning Assessment Scal 
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5.4.3 Comparison of smoking and non-smoking patients during 
the follow-up (Discriminant analyses)
We compared the characteristics of patients who had never smoked with those who 
had smoked at some point (regular or intermittent smokers) in discriminant anal-
yses. According to these analyses, smoking patients were younger, more likely to 
suffer from an alcohol disorder at baseline, exhibited a greater number of Cluster B 
and C symptoms, had a higher frequency of lifetime suicide attempts, higher neu-
roticism, smaller networks, and lower perceived social support than non-smokers. 
All of these variables had at least a moderate correlation in the discriminant func-
tion, but alcohol disorder at baseline and Cluster B and C personality disorders had 
the highest correlations (Table 7). Predicting group membership based on the dis-
criminant function correctly classified 66.5% of the cases.
5.4.4 Covariation of level of depression and smoking
Smoking and depression had only limited covariation (Figure 6). According to au-
toregressive models, level of depression, smoking, and also alcohol use disorders 
all exhibited a strong autoregressive component; depressive symptoms, alcohol use 
disorders, and smoking at t+1 were each best predicted by the respective variable 
at t.
In the analyses at six months path from alcohol use disorder (alco6) to severi-
ty level of depression (depr6) was significant. Depr6 variable explained alco6 varia-
ble in addition to smoking status (smoking6). A packet of cigarettes a day and sub-
stance abuse reflected in the relative sizes of the same effects of topical depression 
symptoms: 2 points and 3 points. In addition at five years the path from smoking 
status (smoking5v) to severity of depression (depr5v) became clear. In additional 
analyses categorical smoking status was replaced with the variable “number of cig-
arettes per day”. Error term arrows were added to those endogenous variables that 
have one (depression and smoking). The equations where alcohol use disorder was 
used as a dependent variable were logistic regressions, which did not have an er-
ror term (Figure 6). While depression and smoking had limited covariation, that 
of smoking and alcohol use disorders needed to be elaborated. At baseline, about 
70% (35/54) of patients with alcohol use disorder were regular smokers, compared 
with 33% (59/177) of patients without an alcohol problem.  The contemporane-
ous correlations of alcohol use disorders and smoking at baseline were significant, 
but just moderately (0.25). From the point of view of estimating model parame-
ters, this correlation (not the percentages) was more relevant. This is true not just 
for the baseline, but also for the other time-points. Thus, the contemporaneous 
correlation between smoking and alcohol use disorders did not create any notable 
problems in the analyses.
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Table 7. Multivariate discriminate analysis of smoking status during the 5-year follow-up 
(n=214).
Variable Coefficienta Correlationb
Age -.406 -432
Alcohol use disorder .400 .544
No. of Cluster B personality disorder symptoms .188 .534
No. of Cluster C personality disorder symptoms .168 .508
Lifetime suicide attempt .289 .422
Neuroticism (at lowest Ham-D) .196 .301
Size of social network -.234 -.473
Perceived social support -.309 -.422
aStandardized canonical discriminant function coefficients
bOverall correlations with the discriminant function in descending order
Figure 6. autoregressive path model of depression, smoking, and alcohol use disorder.
alcohol use 
disorder (bl)
alcohol use 
dis (6 mo)
alcohol use 
dis (18 mo)
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smoking             
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a Hamilton rating scale for depression score
b Number of cigarettes per day (zero or a positive integer, modelled in the Mplus analysis as a continuous variable 
censored from below)
Unstardardized coeffiencts are shown (standardized coefficients are not available, because there are categorical en-
dogenous variables)
2.095 3.333 2.121
0.298 0.487 0.502
n.s. 2.767 3.038 3.948
0.1260.115 n.s. n.s.
1.253  1.325 1.342
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6.1 Main findings   
The most important finding in the first study was that only 57% patients received 
indicated maintenance treatment, and only for 16% of the time indicated; good ad-
herence to pharmacotherapy in the acute phase independently predicted mainte-
nance treatment. The tertiary preventive impact of maintenance treatment may re-
main limited, as many MDD patients either do not receive it, or receive it for a too 
short period. 
Most patients reported positive attitudes towards pharmacotherapy and psy-
chosocial treatments, and good adherence during the follow-up. While attitudes 
became somewhat more critical over time, adherence to psychosocial treatment 
improved, but remained unchanged for pharmacotherapy. Employment predicted 
positive attitude, and larger social network good adherence to pharmacotherapy at 
the last follow-up. Cluster B personality disorder symptoms predicted a negative 
attitude and poor adherence, but cluster C symptoms positive attitude, and living 
alone good adherence to psychosocial treatment.
Factors associated with work disability were: age ≥ 50 years at baseline, sub-
jective experience of inability to work, and introversion. When follow-up variables 
were included, the predictors were age over 50, proportion of time spent depressed, 
number of comorbid somatic disorders and lack of vocational education.   Within 
five years, 20% of the patients belonging to the labour force at baseline were grant-
ed a disability pension. 
The main findings of the last study are the differences between smokers and 
non-smokers. A third of the patients smoked regularly, less than half intermittently, 
and a fifth never. Compared with non-smokers, smokers were younger, had more 
alcohol use disorders, a greater number of Cluster B and C personality disorder 
symptoms, a higher frequency of lifetime suicide attempts, higher neuroticism, 
smaller social networks, and lower perceived social support. Smoking and depres-
sion did not co-vary longitudinally. In contrast, depression, smoking, and alcohol 
use disorders all exhibited strong autoregressive tendencies predicting expecially 
the disorders themselves during follow-up. 
63THL – Research 98 • 2013
6 Discussion
6.2 Methods   
6.2.1 Representativeness of the sample  
The major strength of this present naturalistic study is that it was based on a rel-
atively large (N=269) cohort of both outpatients and inpatients with MDD, ef-
fectively representing psychiatric patients with a new episode of MDD in the city 
of Vantaa. The study was initiated during the era of modern antidepressants and 
maintenance treatment recommendations in the period 1997–1999 within a com-
munity psychiatric setting. On the basis of an epidemiological survey, two-thirds 
of all depressed subjects in the city of Vantaa were treated (within the facilities in-
vestigated) at the time of the study (Rytsälä et al., 2001). 
The different diagnostic criteria, availability of only tricyclic antidepressants, 
and lack of recommendations for widespread maintenance phase treatments are 
all major changes that undermine the generalizability of earlier findings to current 
practice.  The majority of the previous studies have been inpatient or tertiary-care 
studies from major universities, which compromises the epidemiological general-
izability of their findings. 
The study (I–IV) is from the modern era in terms of the use of DSM-IV-TR 
diagnoses and definitions, modern antidepressants, and maintenance treatment 
recommendations. We used structured and semi-structured measures, both objec-
tive and subjective, and investigating a broad range of factors from several other 
domains; socio-demographic factors, work disability factors, clinical variables (in-
cluding axis I, II and III disorders), and temperamental, and psychosocial factors 
(perceived social support, size of social network and negative life events). We used 
a life-chart methodology, which enabled us to investigate maintenance treatment 
endorsements, work ability changes, attitude and adherence to treatment, the sta-
bility of nicotine dependence and the outcome of MDD over time.
6.2.2 Diagnostic measures and life chart methodology
The diagnoses of MDD and comorbid disorders were made using structured and 
semi-structured interviews with excellent reliability (kappa=0.86) for the diagno-
sis of MDD with SCAN, Version 2.0 (Wing et al., 1990). However, the reliability of 
comorbid disorders is unknown. In addition, diagnoses of Axis III disorders were 
based on self-report although only those diagnosed by a physician were included. 
Axis II diagnoses were assessed using the semi-structured SCID-II interview for 
DSM-III-R, as the SCID II for DSM-IV was not yet available in February 1997. Be-
cause of this, it was also used in the 5-year follow-up interviews. Patients were al-
so interviewed with the SCID-II during their depression, which may (Stuart et al., 
1992; Peselow et al., 1994; Ferro et al., 1998), or may not (Loranger et al., 1991) 
have influenced the prevalence of personality disorders. This, as well as the inclu-
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sion of patients with current alcohol use disorders, was done deliberately in order 
to investigate the persistence and effects of these disorders in the follow-up. In the 
5-year follow-up, the SCID-I for DSM–IV–TR Axis I Disorders (First et al., 2002) 
was used instead of SCAN. Sensitivity analyses to ensure uniformity of ratings were 
conducted, and inner consistencies (Cronbach alphas) of the rating scales were also 
checked. No reliability problem that could bias the findings was observed.
Perhaps one of the most influential measurements in this study was the use of 
a life-chart. The longitudinal Interval Follow-up Evaluation (LIFE), a semi-struc-
tured interview and rating system for assessing the longitudinal course of psychi-
atric disorders in sufficient detail to provide the basis for calculating length of ep-
isodes and time to remission, was used for the first time used to investigate the 
outcome of depression in the NIMH-CDS (Keller et al., 1987). In the VDS we used 
a graphical life chart, which is similar, but not identical, to the LIFE method. Unlike 
the latter, patients’ follow-up time was classified into periods of DSM-IV-TR MDE, 
or partial remission (1–4 criteria symptoms) or full remission (no symptoms). 
This is the first long-term prospective study to investigate treatment attitudes 
and adherence among psychiatric patients with MDD. In addition, no prospective 
studies exist on attitude and adherence to psychosocial treatment. Unlike previous 
studies, we were able to investigate the role of a wide variety of variables from dif-
ferent domains as predictors for treatment attitudes and adherence. 
The information on granted disability pensions was based on registers of the 
Social Insurance Institute of Finland, patient records and interviews. The level of 
attrition was low, as 91.3% (230/252) of those in the labour force at baseline con-
tributed to this prospective study. Furthermore, dates of granting the respective 
pensions were granted were recorded in the patient’s life-chart.  The clinical char-
acteristics of patients in the VDS cohort have been reviewed earlier (Melartin et 
al., 2002; Melartin et al., 2004) and are unlikely to differ greatly from those found 
in other studies on psychiatric MDD outpatients. Our findings can probably be 
generalized to those countries with similar health services and disability pension 
systems as in Finland. Treatment and a statement by a psychiatrist are usually re-
quired for disability pension to be granted to a MDD patient in Finland. Thus, the 
coverage with regard to all disability pensions in the study area is likely to be good 
(Isometsä et al., 2000; Sorvaniemi et al., 2003; Honkonen et al., 2007; Raitasalo et 
al., 2010). The SOFAS scale was used to measure global level of functioning at the 
time of evaluation. This scale just measures the level of social and occupational 
functioning, without taking symptoms into account.
To our knowledge, no previous long-term clinical study has investigated varia-
tions in the prevalence of smoking behaviour in MDD patients or the co-variation 
of tobacco smoking and MDD. We examined the aforementioned, also account-
ing for co-variation with comorbid alcohol use disorder, a major confounding fac-
tor. There are few long-term (up to 5 years) prospective studies of cohorts of pa-
tients with MDD and even fewer representative cohorts of outpatients (83% in our 
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study). For all patients, information on smoking was available from three or four 
phases of the longitudinal follow-up. The level of attrition was fairly low, as 79.6% 
(214/269) of the initial cohort contributed to this prospective study. Our evalua-
tion methods included a wide range of predictors; we investigated associations of 
smoking with factors from different domains, including sociodemographic, clin-
ical, comorbidity Axis I-III, and temperamental/personality factors, and we also 
had information on the duration and outcome of depression. 
There are only a few studies of psychiatric comorbidity among primary care 
patients. MDD patients in primary care or psychiatric out-patient settings have 
not been found to differ markedly in current axis I comorbidity (Vuorilehto et al., 
2007). In Primary Care-VDS (PC-VDS) of 137 patients with DSM-IV MDD, 59% 
had at least one current comorbid axis I disorder, any anxiety disorder being the 
most common, 50% (GAD 20%, social phobia 16%, panic disorder 9% and sim-
ple phobia 9%), followed by substance use disorder (16%) and somatoform disor-
der (14%) (Vuorilehto et al., 2005). In VDS approximately half of the patients have 
had a current anxiety disorder and about one fifth a current substance use disor-
der (Melartin et al., 2002).
6.2.3 Study limitations
Two-thirds of the patients participated in the five-year interview, and we had pro-
spective information obtained from patients of varying lengths of follow-up. One 
limitation of the study includes the fact that there was a long interval between the 
last two interviews (3.5 years) and this may have affected the accuracy of informa-
tion regarding longitudinal outcome of maintenance indication (Study I) and the 
information on treatment adherence (Study II). The recurrence rate (and thus on-
set of maintenance indication) may have been slightly underestimated during this 
period. The critical question here is the degree to which adherence during tempo-
rally distant periods could actually differ from temporally close periods. We cannot 
exclude the possibility of a recall bias, but are not aware of any reason why adher-
ence would significantly differ between these periods, in particular as it otherwise 
appears relatively constant during the five-year follow-up. In order to complement 
and check the interview information, we also had access to patient records. With 
regard to measure points, we have only four measure-points in analyses of attitude 
and only three measure-points in analyses of adherence. Minor inaccuracies may 
also exist regarding treatment information. Subjects may also not always have re-
called information on treatment precisely or reported adherence honestly. Howev-
er, data from both subjects themselves and their records were carefully compared 
and synthesized. We defined the indication for maintenance pharmacotherapy to 
begin after three lifetime MDEs, and a different threshold could change the find-
ings. However, setting it to lifetime fourth or fifth episodes in sensitivity analy-
ses resulted in quite similar proportions of patients having received maintenance 
treatment (61.5 and 62.9%, respectively).
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In the second study, the proportion of patients who dropped out of all pro-
spective phases was 11.5% those eligible with 28.5% dropping out of the 5-year fol-
low-up. The drop-outs differed significantly from those participating in terms of 
some socio-demographic characteristics (age, marital status, income) and comor-
bid psychiatric disorders (dysthymia, panic disorder with agoraphobia, alcohol de-
pendence, cluster A and B personality disorder symptoms, and somatic disorders). 
Some of these features were associated with negative, others in turn with positive 
attitude or adherence among those remaining in the cohort. Overall, the drop-outs 
did not differ in terms of baseline attitudes to antidepressant medication or psy-
chosocial treatment. 
Thus, variations in attitudes or adherence could have occurred between inter-
views. Also, patients could perceive or report their adherence as sufficient even if 
the treatment was implemented poorly. Estimates of adherence were based on pa-
tients´ own accounts, albeit evaluated by the interviewer.  In addition, we did not 
inquire about physicians’ attitudes towards medication treatment, which is also im-
portant (Demyttenaere, 2003). Lastly, we used self-developed repeated interviews/
questionnaires, possibly affecting the comparison of our results with those of oth-
ers. However, while the variety of interview measures is a problem in this field, 
our strength was that we asked the same questions repeatedly over time. There 
were some factors that we did not investigate. Evidence suggests that establishing 
a good doctor-patient relationship has an important role in increasing adherence 
(Fawcett, 1995; Paykel, 1995). A clinician´s initial communication style influences 
a patient´s beliefs about and understanding of antidepressants, and  subjects with 
more positive beliefs are more engaged in and satisfied with their treatment (Bult-
man and Svarstad, 2000). 
In the third study, despite a low level of attrition, we had prospective in-
formation obtained from patients of varying lengths of follow-up. The main 
measure of functional ability, the Social and Occupational Functioning Assess-
ment Scale of DSM-IV (SOFAS), includes the ability to work as one of the fac-
tors of functioning, and may thus cause some degree of circularity when used 
as a predictor for a future disability pension. In addition, we did not investi-
gate work motivation, work circumstances (Sanderson et al., 2007), work func-
tioning  (Sanderson et al., 2007; Lagerveld et al., 2010), or patient’s cognitive 
capacity (Raitasalo et al., 2010) which could be of importance. Finally, it is to 
be noted that in order to prospectively analyse predictors, we excluded 17 cas-
es that had already received disability pension at baseline. The total proportion 
of patients who were known to have been granted a disability pension was one 
quarter (25%) of the total cohort (including patients whose diagnoses were 
changed).
In the fourth study, smoking behavior is also a limitation as it was ascertained 
by means of self-reported information. The cohort consisted of depressive psychi-
atric patients, mostly outpatients, all suffering from MDD at baseline, which influ-
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ences the generalizability of our findings. We did not use Fagerström`s question-
naire (Fagerstrom and Schneider, 1989) on nicotine dependence, nor did we have 
information on plasma cotinine concentrations. However, we did collect informa-
tion of smoking behaviour, including number of cigarettes smoked, at three to four 
time-points during the follow-up. In our view, a regular smoker was very likely to 
have true nicotine dependence. Finally, our investigation of co-variation and au-
toregression was limited to three factors, and co-variation with other possible con-
founding factors was not investigated. 
 
6.3 Maintenance pharmacotherapy in MDD  
          (Study I)  
This study investigated the duration, prevalence and predictors of maintenance 
treatment. MDD is a commonly occurring and burdensome disorder and one of 
the most important mental disorders in terms of public health impact. Mainte-
nance therapy is an effective tertiary preventive intervention. National practice 
guidelines recommend maintenance treatment for tertiary prevention of depres-
sive recurrences (APA, 2010; Schaffer et al., 2012) may deny need for treatment fear 
facing their illness as a chronic condition. However, untreated and prolonged de-
pression involves a marked risk of functional disability and days lost from work 
and adversely affect interpersonal relationships. Indeed, it has been shown that 
MDD involves a marked risk of functional disability (Lopez et al., 2006; Rytsälä 
et al., 2006; Holma et al., 2011) and adversely affects interpersonal relationships 
(Wade and Cairney, 2000). Suicide attempts among patients with MDD are strong-
ly associated with the presence and severity of depressive symptoms (Holma et al., 
2010). 
To my knowledge, no previous secondary care long time study has investigat-
ed whether these recommendations have been implemented. In this prospective 
naturalistic 5-year follow-up study, only about half of the subjects with the indica-
tion received the indicated maintenance treatment, and only for about one-sixth of 
the time indicated. Maintenance treatment was best predicted by good medication 
adherence during the acute phase. A third of patients who did not receive indicat-
ed maintenance treatment, had a negative attitude towards longlasting medication. 
The main reason for discontinued antidepressant treatment, was a generally nega-
tive attitude towards medication. 
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6.4 Treatment attitudes and adherence of MDD  
           (Study II)             
Poor adherence to treatment for depression is likely to be common, and an im-
portant limit for what can be realized by treatment. In this prospective long-term 
study, the aim was to investigate temporal patterns of attitudes and adherence to-
wards treatments, and factors influencing these patterns among psychiatric MDD 
subjects. 
Depressive patients attitudes towards pharmacotherapy and psychosocial 
treatments were mostly positive during follow up. However, while the attitudes to-
wards medication and psychosocial treatment became slightly less positive, adher-
ence to treatments either improved or remained similar over time. Attitudes and 
adherence were associated with both psychiatric and psychosocial factors. Employ-
ment predicted a positive attitude towards antidepressants, and a larger social net-
work good adherence. Attitudes and adherence to psychosocial treatments were as-
sociated with type of personality disorders; cluster B personality features predicted 
a negative attitude and poor adherence, while cluster C features predicted a posi-
tive attitude.  
In earlier 6- and 18-month studies of VDS negative treatment attitudes at base-
line were more common towards antidepressants than psychotherapeutic treat-
ments, but in 82% of cases these attitudes become positive during the treatment. 
At baseline, negative attitudes towards treatment were associated with younger 
age, lower anxiety level (BAI), lower depression level (Ham-D), longer duration of 
MDE prior to entry and no current comorbid alcohol use disorder (Melartin et al., 
2005).  In the long-term, the majority of subjects (78.7%) reported a positive at-
titude at their last follow-up, but became slightly less positive over a longer peri-
od. A positive attitude towards medication was associated only with employment, 
not other socio-demographic factors or psychiatric factors. It is important that at 
baseline many patients had no previous treatment experience; during the follow-
up, their personal experiences of treatments received could have increasingly con-
tributed to their attitudes.
In the present study, only a larger social network to be independently associat-
ed with good pharmacotherapy adherence. In a Swedish 2-year study, a finding that 
non-adherent patients were observed to more often be living alone (Akerblad et al., 
2006) was the same as that in the present study. In previous primary care studies 
substance abuse, coexisting personality disorder and unemployment were associat-
ed with poor medication adherence. Personality pathology is thought of as behav-
iour patterns characterized by  limited adaptive capability (American Psychiatric 
Association, 2003). In this study, alcohol dependence and a cluster of C symptoms 
were associated with a positive attitude towards medication, but not antidepres-
sant adherence. Extroversion was associated with non-adherence in a short-term 
antidepressant medication compliance study (Cohen et al., 2004). Association be-
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tween lower rates of narcissistic-histrionic personality disorders was also found 
to be associated with better adherence in one secondary care study (Tedlow et al., 
1996; Tedlow et al., 2002). In one recent secondary study authors found the pre-
dictors for non-adherence to antidepressant continuation and maintenance treat-
ment in recurrently depressed patients to be a higher level of personality pathology 
and, somewhat surprisingly and a higher level of education (ten Doesschate et al., 
2009). In this present study, better adherence was independently associated with 
only larger social network. Surprise, the attitude was not a major predictor of com-
pliance with anti-depressants.
In the present study attitudes towards psychosocial treatment became slightly 
less positive and were associated with psychiatric disorders. A positive attitude to-
wards psychosocial treatment was found to be associated with cluster C personali-
ty disorder, while cluster B personality disorder was associated with a negative atti-
tude. It is probable that the trait of fearfulness characteristic of patients with cluster 
C features can increase positive attitudes. This is because patients with cluster C 
personality have a smaller social network. After all, they are fearful and have a low-
er perceived social support, which obviously makes it difficult for them to establish 
and maintain relationships like marriages. Indeed,   persons lacking marital sup-
port may be more motivated to adhere to psychosocial treatment, perhaps in lieu 
of other social contacts. Some of the factors that were important at baseline such as 
male gender and dysthymia did not remain as important after baseline. Some fac-
tors such as the number of psychiatric disorders, the axis of the number I-III dis-
orders, phobic anxiety, panic disorder without agoraphobia and neuroticism were 
associated with attitudes in univariate analyzes, but not in multivariate analyzes. 
In the present study, only psychiatric features affected attitudes towards psychoso-
cial treatment, while psychosocial situation, gender, age, outpatient status or clini-
cal features of MDD did not. 
Patients’ adherence to psychosocial treatment tended to improve or remained 
similar over time. Cluster B personality disorders were associated with poor adher-
ence and living alone with good adherence. This sounds logical; unstable people 
make unlikely long-term patients as they are not capable of committing to long-
term treatment. Alcohol dependence was a predictor in univariate analyses, but not 
in logistic regression analyses. As well as diagnostic clinical features and psychoso-
cial factors were associated with treatment behaviour. Poor adherence was associ-
ated with psychosocial treatment. Some socio-demographic factors (gender, age of 
onset, functional ability), and clinical factors (suicidal ideation, hopelessness) were 
associated with adherence as trends in univariate analyses, but not in multivariate 
logistic regression models. 
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6.5 MDD and work disability  
          (Study III)
Disability pension was granted on the grounds of MDD would independently be 
predicted by patients’ age, severity of depression, proportion of time depressed 
during follow-up, baseline level of functioning and sick leave.  To the best of my 
knowledge, there are only a few earlier prospective long-term clinical studies that 
exist on disability pensions granted for MDD patients. Accordingly, the factors pre-
dicting disability pensions among psychiatric MDD patients are not well known. 
Current study strengthens the view on MDD being an illness with a potentially 
poor prognosis in terms of working ability, as one fifth of patients were granted a 
disability pension. 
The lack of previous studies on predictors on factors that predict the grant-
ing of a disability pension renders comparison with previous findings difficult. Al-
though predictors for short-term sick leave are not necessarily the same as those 
that predict the granting of a disability pension, medium-term studies of sickness 
absence or work functioning have reported mostly congruent results (Druss et al., 
2000; Kruijshaar et al., 2003; Lerner et al., 2004; Michon et al., 2008). 
In a recent large register-based Finnish study (Korkeila et al., 2010) it was 
found that comprised psychiatric inpatients or outpatients selected for psycho-
therapeutic rehabilitation reported comparable rates of being granted a disability 
pension as those among patients with depression. That study also found patients 
with a principal diagnosis of personality disorder to have a similar risk of having 
to take a disability pension, whereas those with anxiety disorder had a lower risk 
compared with patients who had depression alone. In this study, of comorbid anx-
iety disorders only GAD was a predictor for a disability pension. The study did not 
find any comorbid personality disorder to significantly influence the risk of getting 
a disability pension. In previously study were reported that introverted patients al-
so have lesser social networks, and their subjective social support resumes along 
with recovery from depression to a smaller extent, than among more extrovert-
ed patients (Leskelä et al., 2009). In an earlier phase of the VDS study, Rytsälä and 
co-workers reported that severity and preceding duration of depression among 
MDD’s patients are the major determinants of overall functional ability (SOFAS), 
which probably mediates their influence on the risk of getting a disability pension 
(Rytsälä et al., 2007). The associations between the level of social and occupation-
al functioning and sick leave and perceived (subjective) ability to work with ob-
jective work disability are unavoidably somewhat circular. These variables overlap 
conceptually and are statistically correlated, thus presenting both potential prob-
lems of multicollinearity in multivariate models, as well as difficulties in interpret-
ing the findings. When comparing these objective predictors and subjective view 
on work ability, perceived work ability was in our model the strongest independ-
ent predictor followed by sick leave at baseline, and SOFAS. However, these differ-
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ences may also be influenced by methodological factors, and thus should be inter-
preted cautiously and replicated in future studies. Being on sick leave at baseline 
appears to markedly increase the  risk of becoming superannuated even after ad-
justing for the other major predictors; thus it cannot be excluded that the possibil-
ity that prolonged sick leave for some patients may decrease rather than increase 
their probability of returning to work. The risk of being granted a disability pen-
sion was greatest during the first year of follow-up. However, t this probably also 
reflects the pension system in Finland as a disability pension in Finland is granted 
only after 300 days of sick leave. 
In VDS previous 18-month follow-up, disability pension was predicted by 
older age, longer time being in a depressed state, sense of  hopelessness, and lower 
level of social and occupational functioning at baseline (Rytsälå et al., 2007). The 
longitudinal and recurrent nature of MDD makes the need for investigation of 
long-term predictors obvious. However, remarkably few prospective, comprehen-
sive clinical studies on long-term work disability in psychiatric or primary care ex-
ist.  
Many socio-demographic and clinical factors clearly predict long-term work 
disability among psychiatric patients with MDD even after adjusting for clinical 
variables, age, introversion, perception of being unable to work at baseline, lack of 
vocational education, and higher number of comorbid somatic disorders as inde-
pendent predictors for the granting of future disability pensions. Depression-relat-
ed clinical factors were also important, in particular the time spent in depressive 
episodes during the follow-up. In this study, of comorbid anxiety disorders only 
GAD significantly predicted the granting of a disability pension in univariate anal-
yses. The personality dimension of introversion was a predictor. It is highly corre-
lated with cluster C personality disorders and social phobia (Jylhä et al., 2010) and 
increased the risks of chronicity and recurrence of MDD. A recent Finnish study 
also found that obsessive-compulsive personality disorder is common among oc-
cupational health care clients with depression (Raiskila et al., 2013). In addition, a 
previously report shows that introverted patients also have smaller social networks, 
and their subjective social support increases along with recovery from depression 
to a lesser extent, than among more extroverted patients (Leskelä et al., 2009). Such 
findings may also partly explain the difficulties introvert subjects have in regaining 
their ability to work.  Nevertheless, being older than 50 was the most robust pre-
dictor for the granting of a disability pension. Indeed, one half of those older than 
50 years were granted a disability pension, compared to only one eighth of those 
younger than 50. The proportion of those superannuated was broadly similar to 
that reported by two previous studies, one of which was a general population study 
and the other a psychiatric outpatient study (Sorvaniemi et al., 2003; Doshi et al., 
2008). In previous studies, including our own medium-term study, older age also 
predicted work disability among psychiatric MDD patients (Dewa and Lin, 2000; 
Dewa et al., 2002; Sorvaniemi et al., 2003; Rytsälä et al., 2005; Rytsälä et al., 2007; 
72 THL – Research 98 • 2013
Long-Term Follow-Up Study Focusing on MDD Patients’ 
Maintenance Treatment, Adherence, Disability  and Smoking
Sanderson et al., 2007; Doshi et al., 2008; Lerner and Henke, 2008; Raitasalo et al., 
2010).  Those over 50 did not differ in regard to the duration or severity of depres-
sion or for the overall level of functioning compared to younger age groups. Thus, 
differences in clinical characteristics are unlikely to explain fully the difference in 
risk between age groups. 
6.6 MDD and smoking  
          (Study IV)
Depressed persons smoke a lot, and it must be acknowledged that insuffient atten-
tion is paid to it in psychiatry as it is a serious health risk. In this study, our aim was 
to compare the characteristics of smoking psychiatric MDD patients, and to inves-
tigate whether depression and smoking behavior covary or have an independent 
course. Smoking is very common in this study.
People start smoking before they reach adult age, for which reason we did not 
investigate any cause – effect relationships in our research. This question has been 
studied in adult psychiatric population. Smoking was very common in patients of 
this study, only a fifth of them have never smoked, two-fifth of smokers have in-
termittently, one-third smoked regular during follow-up. This prevalence is even 
higher than in the general Finnish population, which is 22.2% (Pirkola et al., 2006). 
Compared with non-smokers, regularly smoking patients had over four times 
more often alcohol use disorders at baseline. Regularly smoking patients were on 
average three years younger, had higher neuroticism, smaller social networks, and 
lower perceived social support than non-smokers. Of those factors alcohol use dis-
order at baseline and Cluster B and C personality disorders had the highest correla-
tions with smoking. Previous studies are in line with these findings. The link found 
between alcohol use disorders and cigarette smoking for both MDD patients and 
the general population alike is likely due at least in part to common genetic mech-
anisms (Madden et al., 2004). Mood, anxiety, personality and illicit substance use 
disorders were associated with significantly increased risk of persistent nicotine 
dependence. Persistent nicotine dependence was more common among unmar-
ried, younger females with lower income levels and lower educational attainment 
(Goodwin et al., 2011). Current smokers have generally had higher levels of nega-
tive emotionality and less behavioural consistency than former smokers and those 
who have never smoked (Kahler et al., 2009). Previous studies have also demon-
strated a connection between smoking and higher neuroticism, lower extraversion, 
aggression, and lower sociability and constraint (Kubicka et al., 2001; Etter et al., 
2003; Munafo et al., 2007). In an early general study, the prevalence of personali-
ty disorders among smoking individuals has also been observed to be high (Grant 
et al., 2004). In this study were found a similar strong association between smok-
ing and personality traits or disorders among patients with depression; Cluster C 
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personality disorders have been associated with a more chronic outcome of MDD 
(Holma et al., 2008) and Cluster B personality disorders also with alcohol use dis-
orders. A decision to smoke may also have serious consequences on the outcome 
of depression. In the present study, compared with non-smokers, regularly smok-
ing patients had attempted suicide 2.3 times more often prior to follow-up, and 
the lifetime suicide attempts were significantly associated with smoking status. Ac-
cording to a previous 5-year follow-up report the incidence rate of suicide attempts 
was 21-fold during time depressed and fourfold during time in partial remission 
compared with time in full remission (Holma et al., 2010). Smoking patients also 
had a higher frequency of lifetime suicide attempts. Previous reports have shown 
a positive association between suicide and smoking status (Tanskanen et al., 2000; 
Hemmingsson and Kriebel, 2003; Breslau et al., 2005; Bronisch et al., 2008). How-
ever, in our earlier study investigating risk factors for suicidal behaviour, we found 
no independent association with smoking (Sokero et al., 2003). 
Smoking and depression are significant public health problems with multi-
ple etiological dimensions and outcomes. Although each condition is important in 
itself, they are also important because they often potentiate each other. However, 
no previous clinical study has investigated this long-term covariation between de-
pression and smoking. Among patients who are initially depressed, smoking itself 
does not seem to increase their probability of remaining depressive in the future. 
Thus, the idea of smoking itself being depressogenic is not supported by our re-
sults, at least not in subjects who, for whatever reason, are already depressed. Only 
a small number of patients, less than 10% started smoking during the study peri-
od and a similar number had quit smoking, so the proportion of smoking patients 
did not increase during follow-up. Smoking and depression had only limited co-
variation; the level of depression and smoking did not go hand in hand during fol-
low-up. Thus, our findings do not support the self-medication hypothesis. Accord-
ing to autoregressive models, level of depression, smoking, and also alcohol use 
disorders exhibited strong autoregressive tendencies, each having an independent 
course over time. Overall, our findings provide support for neither smoking caus-
ing depression nor depression causing smoking, but are consistent with other fac-
tors causing their co-occurrence. 
Smoking patients differed from non-smoking patients with regard to age, al-
cohol use disorders, personality disorders, lifetime suicide attempts, personality 
factors, and social support. The level of depression and smoking did not go hand 
in hand during the follow-up; they both had an independent course.
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6.7 General Discussion  
The realization of treatment and its consequences do not depend solely on the 
treatment offered but also on individual autonomic decisions. People have the 
power of self-determination; they make their own decisions regarding treatment 
and whether or not they follow recommendations. However, these decisions have 
important consequences. We can influence people by presenting the practical con-
sequences of various decisions, the probability of the recurrence of depression or 
premature retirement if their current depressive state is not treated effectively or 
actively. A patient is an active subject, and not merely an object of treatment. Co-
operation is a key issue for realization of a beneficial treatment, and psychoeduca-
tion is of importance as well. 
Adherence to treatment during the acute phase predicted the realization of in-
dicated maintenance treatment. Many depressive patients in our 18-month study 
reported having taken an active, autonomous role in the decision to terminate an-
tidepressants. A patient´s individual decision was a more common reason than per-
ceived side-effects of antidepressants, poor response, or subjectively perceived re-
covery. In the present 5-year study, premature termination of antidepressants was 
predicted by negative attitudes at entry. Despite expectations, attitude was not a 
major predictor of adherence, and predictors of adherence to psychosocial treat-
ment and antidepressants were different. Attitudes towards psychosocial treatment 
also changed to less positive during follow-up, but adherence improved signifi-
cantly. However, treatment adherence was reportedly good, and the overall atti-
tudes to both antidepressant medication and psychosocial treatment were positive. 
Attitudes to antidepressant medication became less positive during the follow-up, 
but adherence to medication did not change significantly. Discontinuation of psy-
chotherapeutic treatments was associated with more severe and more prolonged 
depressive symptoms.  Noteworthy was also that about a third (32%) of the pa-
tients not achieving full remission during the follow-up were without any psycho-
social treatment at 18 months (Melartin et al., 2005). In the 18 month follow-up 
study less than a fifth (16%) of the patients and only 9.2% at the 5 year follow-
up study received weekly psychotherapy. At the 5 year mark one fourth (24.5%) 
were currently receiving any psychosocial treatment, and nearly half (44.8%) were 
currently using an antidepressant (Holma et al., 2008). Younger age, less severe 
and longer-lasting depression, and milder anxiety symptoms were also associated 
with negative treatment attitudes (Melartin et al., 2005). The patients who received 
psychotherapy were either those able to form a good treatment alliance, and thus 
probably more able to benefit from therapy, or suicidal patients who needed more 
intensive treatment in the acute phase and therefore also received it more promptly. 
Despite recommendations in practice guidelines (NICE, 2009; APA, 2010; Suomen 
Psykiatriyhdistys, 2010; Schaffer et al., 2012) for more intensive treatment, patients 
with personality disorders were the least likely to receive weekly psychotherapy. 
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Non-adherence is rarely an “on-off” phenomenon. Treatments may occur more or 
less irregularly, and it may be unclear whether this significantly affects the achieve-
ment of treatment goals or not. In contrast to the hypotheses those with continued 
self-reported non-adherence to antidepressants were more often those without co-
morbidity, especially without anxiety and avoidant personality disorders (Melar-
tin et al., 2005). It seems that the presence of perceived distress is also a major fac-
tor that drives the continuation of treatment. 
We found that during the five-year follow-up period one fifth of the cohort of 
psychiatric patients with MDD belonging to the labour force at baseline was even-
tually granted a disability pension. Individuals who were granted a disability pen-
sion also spent more time depressed than non-pensioned patients. In addition, 
they had a more subjective understanding of themselves as being unable to work 
markedly more often than their non-pensioned counterparts. Importantly, subjec-
tive perception of work ability at baseline was a more significant predictor of lat-
er retirement over many other possible predictors emphasizing the autonomic na-
ture of this outcome, and may reflect the motivation, strengths, or coping abilities 
of an individual. However, age was the major predictor despite similar severity of 
depression compared to non-pensioned patients. It is possible that the threshold 
for seeking or being granted a disability pension is lower for older subjects, perhaps 
due to the fewer remaining working years and lower total costs of pensions. In any 
case, aging alone is an insufficient explanation. Also the personality structure may 
be important. In previous studies, introversion as a personality dimension  is high-
ly correlated with cluster C personality disorders and social phobia (Jylhä et al., 
2010), both of which increased the risks of chronicity and recurrence within our 
study population (Holma et al., 2008).  A contradictory finding was that cluster C 
personality disorders were associated with a weaker outcome, but a more positive 
attitude to treatment. This may reflect the difficulties common among these pa-
tients to express dissatisfaction. A Canadian study found that personality disorders 
did not affect the results of psychotherapy or medication treatment, but treatment 
by the same psychiatrist leaded to similar outcomes (De Bolle et al., 2011). Longer 
time in MDE prior to entry, severity of depression and anxiety, lower levels of so-
cial and occupational functioning, comorbidity; all these findings support the idea 
that patients should receive effective treatment in order to more likely maintain 
their working ablity.  With aging, these factors are likely to be even more important.
Smoking was very common among depressive patients as only a fifth of them 
have never smoked. Rather than depression or smoking co-varying or predicting 
each other, depression, smoking, and alcohol use disorders each have strong au-
toregressive tendencies, and predicted themselves during follow-up. These findings 
are more consistent with common factors causing their epidemiological associa-
tion than depression resulting in increased smoking or smoking inducing depres-
sion. Smoking initiation is also a person’s autonomous decision, as well as initia-
tion into alcohol use. In this study baseline alcohol use disorder is important, but 
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not as important a prognostic factor as the strength of the depression. While de-
pression and smoking had limited covariation, that of smoking and alcohol use 
disorders needed to be elaborated. Compared with non-smokers, regularly smok-
ing patients had over four times more often alcohol use disorders at baseline. At 
baseline, nearly 70% of patients with alcohol use disorder were regular smokers 
compared with 33% of patients without an alcohol problem.  As smoking in MDD 
patients is strongly associated with several clinically significant characteristics that 
are associated with a negative outcome, there is substantial risk that this will affect 
the findings and lead to false attributions.
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7.1 Conclusions  
In conclusion, in secondary care, maintenance treatment is received by those able 
to adhere with their treatments, a finding which highlights the interactive nature 
of continuity of treatment. The tertiary preventive impact of maintenance treat-
ment for MDD seems currently limited, as many MDD patients may either not re-
ceive it or receive it for too short a period. To ensure generalizability, replication of 
these findings is necessary. 
Depressive psychiatric patients followed up for five years reported attitudes 
and treatment adherence to be mostly positive and good. Even though patients 
accumulated personal experience of various treatments, attitudes and adherence 
changed relatively little over time. However, they were significantly associated with 
both clinical personality disorders and psychosocial factors. Despite expectations, 
attitude was not a major predictor of adherence, and predictors of adherence to 
psychosocial treatment and antidepressants may be different. Attention to adher-
ence of those with cluster B personality disorders or poor social support and those 
who are unemployed may be needed. 
Of psychiatric patients with depression, one fifth was granted a disability pen-
sion within five years. Future disability pension can be predicted by baseline older 
age, especially older than 50 years, personality factors, functional disability, lack of 
vocational education, and comorbid somatic disorders. Longitudinally, accumula-
tion of time spent depressed also appears a decisive factor.  
Among psychiatric MDD patients, smoking is associated with several clinical 
characteristics (particularly substance use disorders) and personality factors (per-
sonality disorders and neuroticism), which may markedly confound research on 
the impact of smoking. Rather than depression or smoking co-varying or predict-
ing each other, depression, smoking, and alcohol use disorders each have strong au-
toregressive tendencies. These findings are reliable with common factors causing 
their epidemiological association.
7.2 Clinical and research implications 
In depression secondary care, maintenance treatment is received by those able to 
adhere with their treatments, a finding which highlights the interactive nature of 
continuity of treatment. Our findings are important from a public health perspec-
tive.  To ensure generalizability, replication of these discoveries is necessary. The 
tertiary preventive impact of maintenance treatment for MDD seems currently 
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limited as many MDD patients may either not receive it or receive it for too short 
a period.                                                                                                                                   
The provision of psychoeducation to all depressive patients (and their fami-
lies) seems important. This should include information on antidepressants - not 
only their side-effects but also their non-addictiveness, and mechanisms of ac-
tion. As the patient’s personal motivation for the implementation of the treatment 
proved important in this study, it is essential to carefully and without judgement 
find out the patient´s own reasons to discontinuation of a medication, and ensure 
that the patient´s view is taken into account, and targeted information given. This 
might prove an effective way to improve continuity of treatments and outcome of 
depression. Moreover, it is important to motivate patients at least to try antide-
pressants, and to regularly ask about their treatment attitudes in order to recognize 
those at risk of non-adherence. 
More research should be conducted on the background to non-adherence and 
discontinuity of treatments in order to better identify patients at specific risk. Fu-
ture research should also include intervention studies and investigations of per-
ceived interaction between patients and the persons administering treatment in 
order to clarify these dimensions of adherence. Special attention should be direct-
ed at improving treatment adherence among those who are unemployed, have had 
unless social support or B personality disorders. Information about treatment ad-
herence and attitude is needed to help to develop better and more effective treat-
ments and treatment facilities, as well as to improve co-operation between various 
treatment settings. More research is also urgently needed on specific psychothera-
pies. In addition, prospective studies should be performed to investigate the effects 
of treatment adherence to outcome of MDD. 
Factors associated with functional and specifically long-term work disability 
have been researched surprisingly seldom. When one takes into account especial-
ly the huge costs connected with depression treatment and the disability it causes, 
this is disturbing. Each year about 4,000 Finns go on disability pension because of 
depression. Pension expenditures for people on disability pension for depression 
have roughly tripled in ten years, and depression as a reason for the granting of a 
disability pension has gradually become more common. Recognition of depression 
and specifically the risk factors associated with functional and work disability such 
as older age, personality factors, objective and subjective functional disability, lack 
of vocational education and somatic comorbidity are key factors in avoiding the 
necessity to superannuate individuals. Research is needed on treatment to better 
identify those special treatment methods that help high risk patients. Time spent 
depressed appears to be decisive factor that has had a special effect on work disabil-
ity. Thus, early commencement of treatment and sufficiency of treatment resourc-
es are necessary despite the current shortage of psychiatrists. Reducing time spent 
depressed by optimal treatment is one of the most important ways to reduce long-
term disability, otherwise prolonged sick-leave or even work disability pensions are 
79THL – Research 98 • 2013
7 Conclusions and future implications
possible results. Problems in the intensity and monitoring of treatment stand in the 
way of patients’ rapid recovery and thus restoration of their functional and work 
disability.  Perceived ability to work is also a predicting factor, suggesting that that 
factors related to the working environment should be investigated in the future. 
Rather than depression or smoking co-varying or predicting each other, de-
pression, smoking, and alcohol use disorders each have strong autoregressive ten-
dencies. These findings are more consistent with common factors causing their 
epidemiological association than depression resulting in increased smoking or 
smoking inducing depression. 
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